date name shares transaction value  tavistock life sciences co investment management    acquisition at  per share   tavistock life sciences co investment management    acquisition at  per share   tavistock life sciences co investment management    acquisition at  per share   tavistock life sciences co investment management    acquisition at  per share   tavistock life sciences co investment management    acquisition at  per share   tavistock life sciences co investment management    acquisition at  per share   tavistock life sciences co investment management    acquisition at  per share   tavistock life sciences co investment management    acquisition at  per share   tavistock life sciences co investment management    acquisition at  per share   tavistock life sciences co investment management    acquisition at  per share   tavistock life sciences co investment management    acquisition at  per share  newslatestcompanyusmrtx marketwatch news on mrtx how led zeppelin would describe this market  pm nov    the trading deck newsnonmarketwatchcompanyusmrtx other news on mrtx mirati therapeutics mrtx rises stock moves  higher  am july    zackscom mirati perks up   pm may    seeking alpha q mirati therapeutics inc  pm may    edgar online  edg  q k mirati pharma what differentiates it from the pack  pm april    seeking alpha k mirati therapeutics inc  pm march    edgar online  edg  q k insiderinsightscom daily round up  ads mrtx ebtc bas  am jan    seeking alpha insiders roundup adobe fedex  pm jan    gurufocuscom insiderinsightscom daily round up  ads mrtx arnc opk  am jan    seeking alpha insiderinsightscom daily round up  vray bas mrti opk  pm jan    seeking alpha insiderinsightscom daily round up  wpx mrti opk  am jan    seeking alpha mirati prices equity offering shares ease  premarket  am jan    seeking alpha  bargains here were the russell s  worst performers in   am jan    seeking alpha how mirati therapeutics mrtx stock stands out in a strong industry  am dec    zackscom q mirati therapeutics inc  pm nov    edgar online  edg  q k biggest movers in manufacturing stocks now – gnca ntla bpmc mrtx  pm oct    investorplacecom biggest movers in manufacturing stocks now – lway lee selb agle  pm oct    investorplacecom biggest movers in manufacturing stocks now – ktov juno ccxi cara  pm sept    investorplacecom biggest movers in manufacturing stocks now – clsd sbbp ahc inve  pm sept    investorplacecom biggest movers in manufacturing stocks now – aks mdgl kin mrtx  pm sept    investorplacecom  biotechnology stocks to sell now  am sept    investorplacecom loading more headlines at a glance mirati therapeutics inc  towne centre drive suite  san diego california  phone   industry biotechnology sector health carelife sciences fiscal yearend  view sec filings revenue na net income m employees  annual report for mrtx newspressreleasecompanyusmrtx press releases on mrtx mirati therapeutics to host key opinion leader breakfast on immunooncology combinations on july  in new york  pm july    pr newswire  prf mirati therapeutics to host key opinion leader breakfast on immunooncology combinations on july  in new york  pm july    pr newswire  prf mirati therapeutics announces appointment of neil reisman to the board of directors  pm june    pr newswire  prf mirati therapeutics to present at the  jefferies global healthcare conference  pm may    pr newswire  prf mirati therapeutics reports first quarter  financial results  pm may    pr newswire  prf mirati therapeutics reports financial results and provides business update for the fourth quarter and full year   pm march    pr newswire  prf mirati therapeutics to present at leerink partners th annual global healthcare conference  pm feb    pr newswire  prf mirati therapeutics announces closing of public offering of common stock and full exercise of underwriters option to purchase additional shares  pm jan    pr newswire  prf mirati therapeutics announces pricing of public offering of common stock  am jan    pr newswire  prf mirati therapeutics provides update on glesatinib and sitravatinib clinical trials and pipeline programs  pm jan    pr newswire  prf mirati therapeutics announces proposed public offering of common stock  pm jan    pr newswire  prf mirati therapeutics reports financial results and provides business update for the third quarter   pm nov    pr newswire  prf mirati therapeutics appoints chris lemasters to role of executive vice president and chief business officer  am oct    pr newswire  prf mirati therapeutics announces appointment of dr bruce la carter to board of directors  am sept    pr newswire  prf histone deacetylases hdac inhibitors market players trends and forecast     pm sept    pr newswire  prf trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york after marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pfacebook hits  billion users earnings beat live blog pstock market ends at record on robust earnings as fed issues policy update ptrump puts his hands together for ‘the late great abraham lincoln’ pthe nintendo switch’s sellout launch in many charts pyear treasury yield falls the most in five weeks after fed statement pfor transgender americans workplace discrimination isn’t limited to the military pyour k match may have some strings attached pthis is the worst mistake people make at work pwhy equalweighted stockmarket indexes bounce back faster from bear markets pnutrisystem shares rally on betterthanexpected earnings pbuffalo wild wings drop  on high chicken wing costs pbreakingf networks shares fall after weak outlook revenue miss pdonald trump is winning the currency cold war pimco phow to thrive at work when your boss wants you to quit pfacebook hits  billion users earnings beat live blog p‘game of thrones’ science let’s take a closer look at that greyscale p‘game of thrones’ the four biggest takeaways from stormborn’ pbreakingnutrisystem shares jump  following q earnings ptop  most annoying people you may want to unfriend on facebook pif you can buy only one stock or etf make it this one loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  news releases  mirati therapeutics skip to content no menu assigned news releases filter releases view all categories mirati methylgene year all years       sort by date descending date ascending update   news releases date title and summary view jul   mirati therapeutics to host key opinion leader breakfast on immunooncology combinations on july  in new york mirati html pdf add to briefcase file is in briefcase jun   mirati therapeutics announces appointment of neil reisman to the board of directors san diego june   prnewswire  mirati therapeutics inc nasdaq mrtx a clinical stage targeted oncology biotechnology company today announced the appointment of neil reisman to the companys board of directors effective immediately mr reisman is a lawyer and certified public accountant with over  years of business experi mirati html pdf add to briefcase file is in briefcase may   mirati therapeutics to present at the  jefferies global healthcare conference san diego may   prnewswire  mirati therapeutics inc nasdaq mrtx a clinical stage targeted oncology biotechnology company will present at the  jefferies global healthcare conference in new york on wednesday june th at  pm et  pm pt charles m baum md phd president and chief executive officer will presen mirati html pdf add to briefcase file is in briefcase may   mirati therapeutics reports first quarter  financial results san diego may   prnewswire  mirati therapeutics inc nasdaq mrtx a clinical stage oncology biotechnology company reported financial results for the first quarter  and provided an update on its product development programs as anticipated  will be an important and defining year for mirati our single agent precision mirati html pdf add to briefcase file is in briefcase mar   mirati therapeutics reports financial results and provides business update for the fourth quarter and full year  san diego march   prnewswire  mirati therapeutics inc nasdaq mrtx the company we our us or mirati today reported financial results for the fourth quarter and year ended december   and provided an update on its product development programs we have made significant progress which positions us to report mirati html pdf add to briefcase file is in briefcase feb   mirati therapeutics to present at leerink partners th annual global healthcare conference san diego feb   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that charles m baum md phd president and ceo of mirati will provide a corporate overview during a fireside chat presentation at the leerink partners th annual global healthcare conference on thursday february   at  pm et am  mirati html pdf add to briefcase file is in briefcase jan   mirati therapeutics announces closing of public offering of common stock and full exercise of underwriters option to purchase additional shares san diego jan   prnewswire  mirati therapeutics inc nasdaq mrtx today announced the closing of its previously announced underwritten public offering of  shares of its common stock at a public offering price of  per share this includes the exercise in full by the underwriter of its option to purchase up to  ad mirati html pdf add to briefcase file is in briefcase jan   mirati therapeutics announces pricing of public offering of common stock san diego jan   prnewswire  mirati therapeutics inc nasdaq mrtx today announced the pricing of an underwritten public offering of  shares of its common stock at a price to the public of  per share in addition and in lieu of common stock mirati is offering to funds affiliated with boxer capital llc prefunded warra mirati html pdf add to briefcase file is in briefcase jan   mirati therapeutics provides update on glesatinib and sitravatinib clinical trials and pipeline programs san diego jan   prnewswire  mirati therapeutics inc mirati or the company nasdaq mrtx today announced data from two ongoing clinical programs including the phase b and phase  trials of glesatinib a spectrum selective kinase inhibitor for the treatment of nonsmall cell lung cancer nsclc patients with genetic alterations of  mirati html pdf add to briefcase file is in briefcase jan   mirati therapeutics announces proposed public offering of common stock san diego jan   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that it intends to offer and sell subject to market and other conditions shares of its common stock mirati expects to grant the underwriters a day option to purchase up to an additional  of the shares of common stock offered in the public offer mirati html pdf add to briefcase file is in briefcase nov   mirati therapeutics reports financial results and provides business update for the third quarter  san diego nov   prnewswire  mirati therapeutics inc nasdaq mrtx the company or mirati today reported financial results for the third quarter ended september   and provided an update on its product development programs we are pleased by the continued progress in all three of our clinical development programs d mirati html pdf add to briefcase file is in briefcase oct   mirati therapeutics appoints chris lemasters to role of executive vice president and chief business officer san diego oct   prnewswire  mirati therapeutics inc nasdaq mrtx today announced the appointment of chris lemasters to the newly created position of executive vice president and chief business officer effective september   chris extensive experience in successfully driving corporate development and strategy at  mirati html pdf add to briefcase file is in briefcase sep   mirati therapeutics announces appointment of dr bruce la carter to board of directors san diego sept   prnewswire  mirati therapeutics inc nasdaq mrtx today announced the appointment of dr bruce la carter to the companys board of directors where he will also serve as a member of the audit committee and compensation committee effective immediately it is a privilege to welcome such a respected and accom mirati html pdf add to briefcase file is in briefcase aug   mirati therapeutics reports financial results and provides business update for the second quarter  san diego aug   prnewswire  mirati therapeutics inc nasdaq mrtx the company or mirati today reported financial results for the second quarter ended june   and provided an update on its product development programs we reported progress across our pipeline during the second quarter including clinical responses mirati html pdf add to briefcase file is in briefcase jun   mirati therapeutics announces change in executive leadership san diego june   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that mark gergen will step down as executive vice president and chief operations officer to pursue other opportunities transitioning over the coming months       we want to thank mark for his important contributions and leadership over the p mirati html pdf add to briefcase file is in briefcase jun   mirati therapeutics provides progress update on current clinical trials san diego june   prnewswire  mirati therapeutics inc nasdaq mrtx today provided an update on three current ongoing clinical programs in patients with nonsmall cell lung cancer nsclc and other solid tumors we are making significant progress in the development of our pipeline as our ongoing clinical programs are showing m mirati html pdf add to briefcase file is in briefcase jun   mirati therapeutics to present at the jefferies  healthcare conference san diego june   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that charles m baum md phd president and ceo of mirati will present a corporate overview at the jefferies  healthcare conference on wednesday june   at  am et  am pt in new york a live audio webcast of the pres mirati html pdf add to briefcase file is in briefcase may   mirati therapeutics to present abstracts on pipeline programs at  american society of clinical oncology asco annual meeting san diego may   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that abstracts on its investigational tyrosine kinase inhibitor candidates glesatinib mgcd and sitravatinib mgcd will be presented at the  american society of clinical oncology asco annual meeting to be held in chicago il from june  mirati html pdf add to briefcase file is in briefcase may   mirati therapeutics reports financial results and business update for the first quarter  san diego may   prnewswire mirati therapeutics inc nasdaq mrtx today reported financial results for the first quarter ended march   and provided an update on its product development programs we are encouraged by the progress made so far this year in advancing our three clinical stage oncology drug candidates which  mirati html pdf add to briefcase file is in briefcase mar   mirati therapeutics to present preclinical data at  american association for cancer research annual meeting san diego march   prnewswire  mirati therapeutics inc nasdaq mrtx today announced it will present preclinical data on two of its three oncology therapies currently in development data on glesatinib mgcd its tyrosine kinase inhibitor targeting met and axl and mocetinostat mgcd its spectrumselective hdac inhibitor wil mirati html pdf add to briefcase file is in briefcase mar   mirati therapeutics announces promotion of jamie a donadio to chief financial officer san diego march   prnewswire  mirati therapeutics inc nasdaq mrtx today announced the promotion of jamie a donadio to senior vice president and chief financial officer effective as of march   mr donadio first joined mirati in  serving as vice president of finance in his new role he will be responsible for a mirati html pdf add to briefcase file is in briefcase mar   mirati therapeutics reports fourth quarter and full year  financial results and provides business update san diego march   prnewswire  mirati therapeutics inc nasdaq mrtx today reported financial results for the fourth quarter and full year ended december   and provided an update on its drug development programs we made significant progress across our entire pipeline in  setting up a potentially transformative year mirati html pdf add to briefcase file is in briefcase mar   mirati therapeutics to present at the barclays global healthcare conference san diego march   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that charles m baum md phd president and ceo of mirati will present a corporate overview at the barclays global healthcare conference on tuesday march   at  pm et  am pt in miami a live audio webcast of the prese mirati html pdf add to briefcase file is in briefcase jan   mirati therapeutics appoints marcy graham vice president investor relations and corporate communications san diego jan   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that marcy graham has been appointed vice president investor relations ir and corporate communications as a seasoned communicator ms graham has more than  years of experience in the biopharmaceutical sector with expertise in growth companies and mirati html pdf add to briefcase file is in briefcase dec   guardant health and mirati therapeutics enter into collaboration on glesatinib mgcd in non small cell lung cancer nsclc trial redwood city calif and san diego dec   prnewswire  guardant health the market leader in liquid biopsies and mirati therapeutics inc mirati nasdaq mrtx a targeted oncology company focusing on genetic and epigenetic drivers of cancer announced today that they have entered into a collaboration for the development of a circu mirati html pdf add to briefcase file is in briefcase dec   foundation medicine and mirati therapeutics collaborate to develop a companion diagnostic for glesatinib mgcd in nonsmall cell lung cancer nsclc cambridge mass and san diego dec   prnewswire  foundation medicine inc nasdaq fmi and mirati therapeutics inc mirati nasdaq mrtx a targeted oncology company focusing on genetic and epigenetic drivers of cancer today announced that they have entered into a collaboration for the development of a companion diagnostic tes mirati html pdf add to briefcase file is in briefcase dec   mirati therapeutics initiates glesatinib mgcd phase  trial in nonsmall cell lung cancer nsclc san diego dec   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the phase  clinical trial of glesatinib mgcd has commenced the company also announced that glesatinib is the proposed generic name for mgcd glesatinib is an inhibitor of the met and axl receptor tyrosine kinase pathways which when al mirati html pdf add to briefcase file is in briefcase dec   mirati therapeutics doses first patient in expansion cohorts of mgcd phase b trial in genetically selected patients san diego dec   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the first patient with nonsmall cell lung cancer nsclc has been dosed in a phase b clinical trial of mgcd the trial will evaluate select patients exhibiting genetic alterations in the tyrosine kinase signaling pathways ret ddr and trk w mirati html pdf add to briefcase file is in briefcase dec   mirati therapeutics to present at the oppenheimer th annual healthcare conference san diego dec  prnewswire  mirati therapeutics inc mirati nasdaq mrtx will be presenting at the oppenheimer th annual healthcare conference on tuesday december   at  am et  am pt in new york charles m baum md phd president and ceo of mirati will provide a corporate overview a live audio  mirati html pdf add to briefcase file is in briefcase nov   mirati therapeutics reports third quarter  financial results and provides business update san diego nov   prnewswire  mirati therapeutics inc mirati nasdaq mrtx today reported financial results for the third quarter ended september   and provided an update on its drug development programs over the last quarter we made substantial progress against our goals including strengthening our balance sheet mirati html pdf add to briefcase file is in briefcase sep   mirati therapeutics presents interim clinical data from ongoing mgcd phase  dose escalation study in patients with advanced solid tumors san diego sept   prnewswire  mirati therapeutics inc mirati nasdaq mrtx an oncology company focusing on genetic and epigenetic drivers of cancer today announced it presented data from the study titled a firstinhuman phase b study of receptor tyrosine kinase rtk inhibitor mgcd in patients with advanced solid tum mirati html pdf add to briefcase file is in briefcase sep   mirati therapeutics announces pricing of public offering of common stock san diego sept   prnewswire  mirati therapeutics inc nasdaq mrtx today announced the pricing of an underwritten public offering of  shares of its common stock at a price to the public of  per share the gross proceeds from this offering are expected to be approximately  million before deducting underwriting d mirati html pdf add to briefcase file is in briefcase sep   mirati therapeutics announces proposed public offering of  million of common stock san diego sept   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that it intends to offer and sell subject to market and other conditions approximately  million of shares of its common stock in an underwritten public offering mirati expects to grant the underwriters a day option to purchase up to an additi mirati html pdf add to briefcase file is in briefcase sep   mirati therapeutics to present clinical data at the european society for medical oncology esmo  european cancer congress san diego sept   prnewswire  mirati therapeutics inc mirati nasdaq mrtx an oncology company focusing on genetic and epigenetic drivers of cancer today announced it will present data on its tyrosine kinase inhibitor mgcd at the esmo  european cancer congress being held in vienna austria from september    mirati html pdf add to briefcase file is in briefcase sep   mgcd demonstrates clinical efficacy with confirmed responses in nsclc patients with met and axl gene amplification denver sept   prnewswire  mirati therapeutics inc mirati nasdaq mrtx an oncology company focusing on genetic and epigenetic drivers of cancer today announced it will present data at the international association of lung cancer iaslc th world conference on lung cancer on the first nonsmall cell lung cancer nsclc patient mirati html pdf add to briefcase file is in briefcase aug   mirati therapeutics to present preclinical and clinical data at the iaslc th world conference on lung cancer san diego aug   prnewswire  mirati therapeutics inc mirati nasdaq mrtx an oncology company focusing on genetic and epigenetic drivers of cancer today announced it will present data on its two tyrosine kinase inhibitors mgcd and mgcd at the international association of lung cancer iaslc th world conference on lung mirati html pdf add to briefcase file is in briefcase aug   mirati therapeutics reports second quarter  financial results and provides business update san diego aug   prnewswire  mirati therapeutics inc mirati nasdaq mrtx today reported financial results for the second quarter ended june   and provided an update on its drug development programs at this years asco meeting we presented initial clinical data on our lead tyrosine kinase inhibitor mgcd whic mirati html pdf add to briefcase file is in briefcase aug   mirati therapeutics and medimmune partner on immunooncology combination in lung cancer san diego and gaithersburg md aug   prnewswire  mirati therapeutics inc mirati nasdaq mrtx an oncology company focusing on genetic and epigenetic drivers of cancer and medimmune the global biologics research and development arm of astrazeneca today announced they have entered into an exclusive clinical trial collaboration mirati html pdf add to briefcase file is in briefcase aug   mirati therapeutics to present at the  wedbush pacgrow healthcare conference san diego aug   prnewswire  mirati therapeutics inc mirati nasdaq mrtx  a targeted oncology company focusing on genetic and epigenetic drivers of cancer will be presenting at the  wedbush pacgrow healthcare conference on tuesday august   at  pm et  am pt in new york charles m baum md phd pr mirati html pdf add to briefcase file is in briefcase may   initial data from ongoing expansion study of mgcd show preliminary evidence of clinical efficacy in heavily pretreated nonsmall cell lung cancer nsclc patients with met gene alterations chicago may   prnewswire  mirati therapeutics inc mirati nasdaq mrtx today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate mgcd as part of the developmental therapeutics category at the  american society of clinical oncolog mirati html pdf add to briefcase file is in briefcase may   mirati therapeutics to present at the jefferies  global healthcare conference san diego may   prnewswire  mirati therapeutics inc mirati nasdaq mrtx will be presenting at the jefferies  global healthcare conference on wednesday june  at  am et  am pt in new york charles m baum md phd president and ceo of mirati will provide a corporate overview a live audio webcast o mirati html pdf add to briefcase file is in briefcase may   mirati therapeutics to provide updates on pipeline programs at  asco annual meeting san diego may   prnewswire  mirati therapeutics inc mirati nasdaq mrtx today announced that the company will provide an update on its investigational targeted tyrosine kinase inhibitor candidates mgcd and mgcd and spectrumselective hdac inhibitor mocetinostat at the  american society of clinical oncology asco a mirati html pdf add to briefcase file is in briefcase may   mirati therapeutics reports first quarter  financial results and provides business update san diego may   prnewswire  mirati therapeutics inc mirati nasdaq mrtx today reported financial results for the first quarter ended march   and provided an update on its drug development programs we continue to make progress across our targeted oncology clinical programs said charles m baum md phd pres mirati html pdf add to briefcase file is in briefcase mar   mirati therapeutics reports fourth quarter and full year  financial results and provides business update san diego march   prnewswire  mirati therapeutics inc mirati nasdaq mrtx today reported financial results for the fourth quarter and twelve months ended december   and provided an update on its drug development programs mirati was built on the premise that the best way to improve outcomes for patients with canc mirati html pdf add to briefcase file is in briefcase feb   mirati therapeutics announces closing of public offering of common stock and full exercise of underwriters option to purchase additional shares san diego feb   prnewswire  mirati therapeutics inc nasdaq mrtx today announced the closing of its previously announced underwritten public offering of  shares of its common stock at a public offering price of  per share this includes the exercise in full by the underwriters of their option to purchase up to  mirati html pdf add to briefcase file is in briefcase jan   mirati therapeutics to present at the leerink global healthcare conference san diego jan   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the company will present a business overview and update at the leerink global healthcare conference on thursday february   at  am eastern time in new york  a live audio webcast of the presentation will be accessible on the in mirati html pdf add to briefcase file is in briefcase jan   mirati therapeutics prices public offering of common stock san diego jan   prnewswire  mirati therapeutics inc nasdaq mrtx today announced the pricing of an underwritten public offering of  shares of its common stock offered at a price to the public of  per share the gross proceeds from this offering to mirati are expected to be  million before deducting underwritin mirati html pdf add to briefcase file is in briefcase jan   mirati therapeutics announces proposed public offering of common stock san diego jan   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that it intends to offer and sell subject to market and other conditions shares of its common stock in an underwritten public offering mirati expects to grant the underwriters a day option to purchase up to an additional  of the shares of comm mirati html pdf add to briefcase file is in briefcase jan   mirati therapeutics doses first patient in phase  study of mocetinostat in bladder cancer patients with genetic alterations of crebbp and ep san diego jan   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the first patient has been dosed in a phase  clinical trial designed to evaluate the efficacy safety and pharmacokinetics of mocetinostat as a treatment for a select group of patients with bladder cancer the trial will enroll patients whose tumo mirati html pdf add to briefcase file is in briefcase jan   mirati therapeutics doses first patient in investigatorsponsored phase  study of mocetinostat in nonhodgkins lymphoma san diego jan   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that memorial sloan kettering cancer center in new york has dosed the first patient in an investigatorsponsored phase  clinical trial of mocetinostat in patients with relapsed and refractory diffuse large bcell lymphoma dlbcl and follicular lympho mirati html pdf add to briefcase file is in briefcase dec   mirati therapeutics doses first patient in expansion cohorts of phase b trial of mgcd in genetically selected patients san diego dec   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the first patient with nonsmall cell lung cancer nsclc has been dosed in a phase b clinical trial of mgcd in selected patients exhibiting genetic alterations of met or axl in this segment of the study one of the expansion cohorts will enr mirati html pdf add to briefcase file is in briefcase nov   mirati therapeutics to present at the th annual piper jaffray healthcare conference san diego nov   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the company will present a business overview and update at the th annual piper jaffray healthcare conference on tuesday december   at  am eastern time in new york  a live audio webcast of the presentation will be accessibl mirati html pdf add to briefcase file is in briefcase nov   mirati therapeutics reports third quarter  financial results and provides business update san diego nov   prnewswire  mirati therapeutics inc mirati nasdaq mrtx today reported financial results for the third quarter ended september   and provided an update on its drug development programs we are excited to report that each of our clinical oncology programs are advancing and are positioned to delive mirati html pdf add to briefcase file is in briefcase nov   michael grey joins mirati therapeutics board of directors san diego nov   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that biotechnology industry veteran michael grey has joined its board of directors mikes extensive experience in the pharmaceutical and biotechnology industries including senior leadership and board positions in several successful companies mirati html pdf add to briefcase file is in briefcase sep   mirati therapeutics to present at biocenturys newsmakers in the biotech industry conference san diego sept   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the company will present a business overview and update at biocenturys st annual newsmakers in the biotech industry conference on friday september   at  am eastern time in new york  a live audio webcast of the presentat mirati html pdf add to briefcase file is in briefcase sep   mirati therapeutics initiates phase  study of mgcd for nonsmall cell lung cancer and other advanced solid tumors san diego sept   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the first patient has been dosed in its phase  clinical study of mgcd in the treatment of patients with advanced solid tumors with an initial focus on nonsmall cell lung cancer nsclc mgcd is a receptor tyrosine kinase rtk inhibitor w mirati html pdf add to briefcase file is in briefcase aug   mirati therapeutics receives orphan designation from us food  drug administration for mocetinostat in diffuse large bcell lymphoma san diego aug   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the us fda has granted orphan drug designation to mocetinostat a spectrum selective hdac inhibitor for diffuse large bcell lymphoma dlbcl in june mocetinostat was granted orphan drug designation as a treatment for myelodysplastic syndrome mirati html pdf add to briefcase file is in briefcase aug   mirati therapeutics reports second quarter  financial results and provides business update san diego aug   prnewswire  mirati therapeutics inc mirati nasdaq mrtx today reported financial results for the second quarter ended june   and provided an update on its drug development programs in the past quarter we expanded the scope of our clinical programs identified compelling patient selection strategi mirati html pdf add to briefcase file is in briefcase jun   mirati therapeutics added to russell  index san diego june   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the company has been added to the russell ® index following the annual reconstitution of its us and global equity indexes on june     inclusion in the russell index charts a step in the rapid growth and maturation of mir mirati html pdf add to briefcase file is in briefcase jun   mirati therapeutics receives orphan drug designation from us food  drug administration for mocetinostat in myelodysplastic syndrome san diego june   prnewswire  mirati therapeutics inc nasdaq mrtx announced that mocetinostat the companys spectrum selective hdac inhibitor has been granted orphan drug designation by the us food  drug administration as a treatment for myelodysplastic syndrome mds mocetinostat is being developed in phase  clinical studies mirati html pdf add to briefcase file is in briefcase jun   mirati therapeutics to present at the th annual jmp securities healthcare conference san diego june   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the company will present at the th annual jmp securities healthcare conference on wednesday june   at  am eastern time in new york   a live audio webcast of the presentation will be accessible on the investors page of the co mirati html pdf add to briefcase file is in briefcase may   mirati therapeutics to present at the jefferies  global healthcare conference san diego may   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the company will present at the jefferies  global healthcare conference on june   at  pm eastern time in new york   a live audio webcast of the presentation will be accessible on the investors page of the companys website a mirati html pdf add to briefcase file is in briefcase may   mirati therapeutics reports first quarter  financial results and provides business update san diego may   prnewswire  mirati therapeutics inc mirati nasdaq mrtx today reported financial results for the first quarter ended march   and provided an update on drug development programs we are making progress in each of our development programs and were on track to produce proof of concept data in multip mirati html pdf add to briefcase file is in briefcase mar   william r ringo joins mirati board of directors san diego march   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that biotechnology industry veteran william ringo has joined its board of directors bill has excellent experience in developing and driving strategies that have enabled success for both large pharmaceutical companies and startup biotechs bi mirati html pdf add to briefcase file is in briefcase mar   mirati therapeutics reports fourth quarter and full year  financial results san diego march   prnewswire  mirati therapeutics inc mirati nasdaq mrtx today reported financial results for the fourth quarter and year ended december   and provided a corporate update  corporate highlights completed transformational corporate reorganization by recruiting highly experienced prec mirati html pdf add to briefcase file is in briefcase feb   mirati therapeutics to present at the  leerink global healthcare conference san diego feb   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the company will present at the  leerink global healthcare conference on thursday february  at  pm eastern time in new york   a live audio webcast of the presentation will be accessible on the investors page of the companys webs mirati html pdf add to briefcase file is in briefcase dec   mirati presents clinical response results of mocetinostat in combination with azacitidine as a treatment for mds san diego dec   prnewswire  mirati therapeutics inc mirati nasdaq mrtx today presented data at the  american society of hematology ash annual meeting demonstrating promising clinical response rates in patients with myelodysplastic syndromes mds patients treated with mocetinostat in combination with azacitidine  separat mirati html pdf add to briefcase file is in briefcase dec   updated presentation time mirati therapeutics to present at the th annual piper jaffray healthcare conference san diego dec   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the company will present at the th annual piper jaffray healthcare conference on wednesday december   at  am eastern time in new york   a live audio webcast of the presentation will be accessible on the investors page of the c mirati html pdf add to briefcase file is in briefcase nov   mirati therapeutics to present at the th annual piper jaffray healthcare conference san diego nov   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the company will present at the th annual piper jaffray healthcare conference on wednesday december   at  pm eastern time in new york   a live audio webcast of the presentation will be accessible on the investors page of the c mirati html pdf add to briefcase file is in briefcase nov   mirati therapeutics reports third quarter  financial results san diego nov   prnewswire  mirati therapeutics inc mirati nasdaq mrtx today reported financial results for the third quarter and nine months ended september   recent corporate highlights completed financing that generated net proceeds of  million strengthened our worldclass precision medic mirati html pdf add to briefcase file is in briefcase nov   mirati therapeutics to present data on phase  trial of mocetinostat at the th american society of hematology annual meeting san diego nov   prnewswire  mirati therapeutics inc mirati nasdaq mrtx today announced that it will be presenting phase  data on mocetinostat in myelodysplastic syndromes mds at the th american society of hematology annual meeting taking place december  in new orleans data to be presented demonstrates promising clin mirati html pdf add to briefcase file is in briefcase oct   mirati therapeutics prices public offering of common stock san diego oct   prnewswire  mirati therapeutics inc nasdaq mrtx today announced the pricing of an underwritten public offering of  shares of its common stock at a price to the public of  per share  the gross proceeds from this offering to mirati are expected to be approximately  million before deducting under mirati html pdf add to briefcase file is in briefcase oct   mirati therapeutics announces public offering of common stock san diego oct   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that it is offering to sell  shares of its common stock in an underwritten public offering mirati also expects to grant the underwriters a day option to purchase up to an additional  of the shares of common stock offered in the public o mirati html pdf add to briefcase file is in briefcase sep   mirati therapeutics appoints isan chen as chief medical and development officer and adds craig johnson to board of directors san diego californiamarketwired  sep    mirati therapeutics mrtx today announced the appointment of isan chen md as chief medical and development officer as well as the appointment of craig johnson to its bo mirati html pdf add to briefcase file is in briefcase aug   mirati therapeutics reports second quarter  financial results san diego california august   – mirati therapeutics inc “mirati” nasdaq mrtx today reported financial results for the second quarter and first six months ended june   corporate highlights during mirati html pdf add to briefcase file is in briefcase jul   mirati therapeutics to voluntarily delist from tsx san diego california july   – mirati therapeutics inc “mirati therapeutics” today announced that consistent with its previously disclosed plans it has applied to the toronto stock exchange “tsx” to voluntarily delist from trading its shares of common stock  effective at market close on  mirati html pdf add to briefcase file is in briefcase jul   mirati therapeutics to commence trading on the nasdaq san diego california july   – mirati therapeutics inc “mirati therapeutics” or the “company” today announced that the nasdaq capital market “nasdaq” has informed the company that its common stock will commence trading on the nasdaq beginning today july   under the ticker symbol  mirati html pdf add to briefcase file is in briefcase jun   mirati therapeutics and methylgene announce completion of plan of arrangement san diego california and montreal canada june   –methylgene inc “methylgene” tsxmyg and mirati therapeutics inc “mirati therapeutics” today announced the successful completion effective june   of the previously announced plan of arrangement the “arrangement” w mirati html pdf add to briefcase file is in briefcase jun   methylgene shareholders approve the plan of arrangement to reincorporate in the united states as mirati therapeutics inc montreal canada june   –methylgene inc “methylgene” tsxmyg today announced that at its annual and special meeting of shareholders held in montreal quebec the “meeting” that over  of the votes cast by shareholders approved the previously announced plan of arrangement the  methylgene html pdf add to briefcase file is in briefcase jun   methylgene presents clinical data on mocetinostat at the  american society of clinical oncology asco annual meeting montreal canada june   – methylgene inc tsxmyg today announced that clinical data for mocetinostat the spectrum selective histone deacetylase hdac inhibitor was presented at the  asco annual meeting in chicago illinois abstract  – poster – a phase i methylgene html pdf add to briefcase file is in briefcase may   methylgene to present at the jefferies  healthcare conference montreal canada may   – methylgene inc tsxmyg today announced that charles baum md phd president and chief executive officer will present an overview of the company at the jefferies  healthcare conference which will be held in new york city june   the jefferies healthcare conference is one of the methylgene html pdf add to briefcase file is in briefcase may   methylgene to present mocetinostat data at the  american society of clinical oncology asco annual meeting montreal canada may   – methylgene inc tsxmyg today announced that clinical data for mocetinostat the spectrum selective histone deacetylase hdac inhibitor will be presented at the  asco annual meeting to be held in chicago illinois from may st to june   data will be presented from two phase ii clinic methylgene html pdf add to briefcase file is in briefcase may   methylgene reports first quarter  financial results montreal canada may   – methylgene inc “methylgene” or the “company” tsx myg today reported financial results for the first quarter ended march   corporate highlights on may   we announced that subject to court approval and appro methylgene html pdf add to briefcase file is in briefcase may   methylgene announces plan to reincorporate in the united states as mirati therapeutics inc and list on the nasdaq montreal canada may   – methylgene inc “methylgene”tsxmyg today announced that its board of directors the “board” after careful analysis consideration and advice methylgene mirati html pdf add to briefcase file is in briefcase apr   methylgene presents preclinical data on mgcd at the aacr montreal canada april   – methylgene inc tsxmyg today announced that preclinical data for the kinase inhibitor mg was presented at the american association for cancer research aacr annual meeting held in washington dc in a poster entitled “preclinical characteriz methylgene html pdf add to briefcase file is in briefcase mar   methylgene reports results of phase ii trial of mgcd montreal canada march   – methylgene inc tsxmyg today reported topline results from its human efficacy trial trial  with mgcd a novel antifungal agent targeting the fungal enzyme hos  trial  was a randomized multicenter doubleblind placeboco methylgene html pdf add to briefcase file is in briefcase mar   methylgene announces management changes montreal canada march   – methylgene inc “methylgene” or the “company” tsx myg today announced that messrs jeffrey m besterman phd executive vice president research and development and chief scientific officer joe walewicz vice president of business and corporate development a methylgene html pdf add to briefcase file is in briefcase mar   methylgene reports fourth quarter and full year  financial results montreal canada  march   – methylgene inc tsx myg today reported financial results for the fourth quarter and full year ended december   highlights on november   we announced the appointment of charles m baum md phd as president and chief executive  methylgene html pdf add to briefcase file is in briefcase feb   methylgene announces the appointment of mark j gergen as executive vice president and coo montreal canada february   – methylgene inc “methylgene” or the “company” tsx myg today announced that mark j gergen has been appointed to the position of executive vice president and chief operations officer effective immediately in this new role mr gergen will have broad responsibility for business operat methylgene html pdf add to briefcase file is in briefcase dec   methylgene completes enrollment in phase ii trial of mgcd montreal canada december   – methylgene inc tsxmyg today announced that it has completed enrollment in its multicenter randomized doubleblind placebocontrolled trial trial  evaluating mgcd plus fluconazole versus fluconazole alone in patients with moderatetosev methylgene html pdf add to briefcase file is in briefcase nov   methylgene closes cdn million private placement montreal quebec november   – methylgene inc tsxmyg announced today it has completed its previously announced private placement of  units at a subscription price per unit of cdn the “subscription price” each unit consisting of one common share and thirty onehundredths  o methylgene html pdf add to briefcase file is in briefcase nov   methylgene reports third quarter  financial results and provides corporate update montreal canada november   – methylgene inc tsx myg today reported financial results for the third quarter ended september   and provided a corporate update highlights on november   we announced the appointment of dr charles baum md phd as the presiden methylgene html pdf add to briefcase file is in briefcase nov   methylgene announces cdn million private placement montreal quebec november   – methylgene inc tsxmyg announced today its intention to complete a private placement in the united states of cdn million the “offering” the lead investor of the offering is tavistock life sciences “tavistock” an insider of the company and o methylgene html pdf add to briefcase file is in briefcase nov   methylgene announces the appointment of dr charles m baum as president and ceo and changes to the board of directors montreal canada november   – methylgene inc “methylgene” or the “company” tsx myg today announced that charles m baum md phd has been appointed to the position of president and chief executive officer and has joined the company’s board of directors effective immediately me methylgene html pdf add to briefcase file is in briefcase nov   methylgene presents mgcd data at the th eortcnciaacr symposium on molecular targets and cancer therapeutics montreal canada thursday november   – methylgene inc tsx myg today announced that data for the clinicalstage metvegfr inhibitor mgcd was presented at the th eortcnciaacr symposium on molecular targets and cancer therapeutics in dublin ireland in the poster entitled “a novel assay for methylgene html pdf add to briefcase file is in briefcase oct   methylgene to present mgcd data at the th eortcnciaacr symposium on molecular targets and cancer therapeutics montreal canada wednesday october   – methylgene inc tsx myg today announced that preclinical data for its clinicalstage metvegfr inhibitor mgcd will be presented at the th eortcnciaacr symposium on molecular targets and cancer therapeutics taking place in dublin ireland from november  to  methylgene html pdf add to briefcase file is in briefcase oct   methylgene announces presentation of mgcd phase i clinical data at idweek™  montreal canada october   – methylgene inc tsx myg today announced that phase i data for its novel clinicalstage antifungal mgcd were presented at the  idweek™ meeting held in san diego california from october   data describing the safety and pharmacokinetics of mgcd in four phase i clini methylgene html pdf add to briefcase file is in briefcase oct   methylgene provides clinical update on its mgcd novel antifungal therapeutic program montreal canada october   – methylgene inc tsxmyg today provided a clinical update on mgcd the novel orally available antifungal agent clinical data from four phase i safety trials of mgcd will be presented at the  idweek™ meeting to be held in san diego california from october    methylgene html pdf add to briefcase file is in briefcase oct   methylgene presents clinical data on mgcd at the european society for medical oncology esmo  congress montreal canada october   – methylgene inc tsx myg announced that clinical data from its mgcd metvegfrtargeted oncology program were presented today at the european society for medical oncology esmo  congress held in vienna austria  three poster presentations provided updates on the ongoing monotherap methylgene html pdf add to briefcase file is in briefcase sep   methylgene announces change of president and ceo montréal canada september   – methylgene inc “methylgene” or the “company” tsx myg announced today that mr charles grubsztajn has left the company as president and chief executive officer effective immediately and will resign as director of the company  dr martin godbout cha methylgene html pdf add to briefcase file is in briefcase sep   methylgene presents mgcd data at the  annual interscience conference on antimicrobial agents and chemotherapy icaac montreal canada september   – methylgene inc tsxmyg today announced that preclinical data for its novel clinicalstage antifungal mgcd was presented at the nd interscience conference on antimicrobial agents and chemotherapy icaac taking place in san francisco california the poster entitled “ methylgene html pdf add to briefcase file is in briefcase sep   methylgene to present mgcd data at the  annual interscience conference on antimicrobial agents and chemotherapy icaac montreal canada september   – methylgene inc tsxmyg today announced that preclinical data for its novel clinicalstage antifungal mgcd will be presented at the nd interscience conference on antimicrobial agents and chemotherapy icaac taking place in san francisco california from september  to methylgene html pdf add to briefcase file is in briefcase aug   methylgene to present at the  stifel nicolaus healthcare conference montreal canada august   – methylgene inc tsxmyg today announced that mr charles grubsztajn president and chief executive officer will present an overview of the company at the  stifel nicolaus healthcare conference on wednesday september   at  am edt at the four seasons hotel boston massachus methylgene html pdf add to briefcase file is in briefcase aug   methylgene reports second quarter  financial results and provides an update on its clinical programs montreal canada august   – methylgene inc tsx myg today reported financial results for the second quarter ended june   and provided an update on its clinical programs highlights as of august st over one third of the patients have been enrolled in the first phase ii tria methylgene html pdf add to briefcase file is in briefcase jul   methylgene to present at the seventh annual jmp securities healthcare conference montreal canada july   – methylgene inc tsxmyg today announced that mr charles grubsztajn president and chief executive officer will present an overview of the company at the seventh annual jmp securities healthcare conference which will be held at the peninsula new york hotel new york city mr methylgene html pdf add to briefcase file is in briefcase jun   methylgene announces the appointment of dr rodney lappe to its board of directors montreal canada june   – methylgene inc tsx myg today announced the election of rodney lappe phd to the company’s board of directors at the company’s annual meeting of shareholders held earlier today   “over the past year we have significantly enhanced our management team while adding four industry le methylgene html pdf add to briefcase file is in briefcase jun   methylgene to present at the bloom burton  co healthcare investor conference montreal canada june   – methylgene inc tsxmyg today announced that mr charles grubsztajn president and chief executive officer will present an overview of the company at the bloom burton  co healthcare investor conference which will be held at the toronto board of trade on thursday june  methylgene html pdf add to briefcase file is in briefcase jun   methylgene presents mgcd data at the  american society of clinical oncology asco annual meeting montreal canada june   – methylgene inc tsxmyg today announced that clinical data for its metvegfr multi kinase inhibitor mgcd was presented in a poster session at the  asco annual meeting held in chicago illinois the poster entitled “mgcd a multitargeted oral tyrosine kinase recept methylgene html pdf add to briefcase file is in briefcase may   methylgene to present mgcd data at the  american society of clinical oncology asco annual meeting montreal canada may   – methylgene inc tsxmyg today announced that clinical data for its metvegfr kinase inhibitor mgcd will be presented at the  asco annual meeting to be held in chicago illinois from june  to   this poster presentation will highlight the safety profile of mgc methylgene html pdf add to briefcase file is in briefcase may   methylgene to present at biofinance  conference montreal canada may   – methylgene inc tsxmyg today announced that mr joseph walewicz vice president business and corporate development will present an overview of the company at the biofinance  conference which will be held at the st andrew’s club  conference centre in toronto mr walewicz will be pres methylgene html pdf add to briefcase file is in briefcase may   methylgene reports first quarter  financial results and provides an update on clinical programs montreal canada  may   – methylgene inc tsx myg today reported financial results for the first quarter ended march   and provided an update on clinical programs  highlights  rachel w humphrey md was appointed as executive vice president and chief methylgene html pdf add to briefcase file is in briefcase apr   methylgene presents preclinical data for mgcd at the american association for cancer research aacr annual meeting montreal canada april   – methylgene inc tsxmyg today disclosed preclinical data during a presentation for its proprietary multitargeted kinase inhibitor mgcd at the  aacr annual meeting held in chicago illinois results were presented showing the potent inhibition of tumor growth  methylgene html pdf add to briefcase file is in briefcase mar   methylgene to present at the american association for cancer research aacr annual meeting montreal quebec march   – methylgene inc tsxmyg today announced that preclinical data for its multitargeted kinase inhibitor mgcd will be reported in a poster session at the  american association for cancer research aacr annual meeting to be held in chicago illinois from march  to a methylgene html pdf add to briefcase file is in briefcase mar   methylgene announces the appointment of peggy mulligan to its board of directors montreal quebec march   – methylgene inc tsx myg today announced the appointment of peggy mulligan fca to the company’s board of directors “peggy is a financial and audit expert and a well respected business leader we look forward to her guidance as we plan for the future” said charles grubsztajn pre methylgene html pdf add to briefcase file is in briefcase mar   methylgene reports fourth quarter and full year  financial results montreal quebec  march   – methylgene inc tsx myg today reported financial results for the fourth quarter and full year ended december   highlights during the fourth quarter we commenced our first randomized controlled phase  study with mgcd and our two phase  dose escalation  methylgene html pdf add to briefcase file is in briefcase feb   methylgene to present at the th annual bio ceo  investor conference montreal canada  february   – methylgene inc tsx myg announced today that mr charles grubsztajn president and chief executive officer will present a corporate overview of the company on monday february  at  pm est at the th annual bio ceo  investor conference the event is being held at the wa methylgene html pdf add to briefcase file is in briefcase feb   methylgene announces the appointment of dr henry j fuchs to its board of directors montreal quebec february   – methylgene inc tsx myg is pleased to announce the appointment of dr henry j fuchs to the company’s board of directors “dr fuchs is a highly regarded leader in the biotechnology industry and brings a wealth of drug development and management experience at public life science  methylgene html pdf add to briefcase file is in briefcase jan   methylgene announces the appointment of rachel humphrey md as executive vice president and chief medical officer montreal quebec january   – methylgene inc tsx myg today announced the appointment of rachel humphrey md to the post of executive vice president and chief medical officer dr humphrey is board certified in medical oncology and has led the development of multiple oncology agents two of which are currently commerciali methylgene html pdf add to briefcase file is in briefcase page     next last   view all items  add release to briefcase briefcase briefcase printed materials printed materials email alerts email alerts snapshot snapshot rss rss print print email page email page share share search search facebook google linkedin twitter email rss targeted oncology genetic alterations epigenetic alterations pipelineglesatinib mgcd sitravatinib mgcdmocetinostat mgcd patients about the company board of directors scientific advisory board business development careers our team contact us privacy policy terms of use investors news releases events  presentations stock information financials  filings corporate governance investor faqs ir contact email alerts contact mirati  towne centre drive suite  san diego ca   infomiraticom   mirati therapeutics inc  mirati therapeutics  web structure webwizards targeted oncology genetic alterations epigenetic alterations company board of directors scientific advisory board business development careers management team contact pipeline glesatinib mgcd sitravatinib mgcd mocetinostat mgcd patients investors news releases events  presentations stock information financials  filings corporate governance investor faqs ir contact email alerts contact news releases  mirati therapeutics skip to content no menu assigned news releases filter releases view all categories mirati methylgene year all years       sort by date descending date ascending update   news releases date title and summary view jul   mirati therapeutics to host key opinion leader breakfast on immunooncology combinations on july  in new york mirati html pdf add to briefcase file is in briefcase jun   mirati therapeutics announces appointment of neil reisman to the board of directors san diego june   prnewswire  mirati therapeutics inc nasdaq mrtx a clinical stage targeted oncology biotechnology company today announced the appointment of neil reisman to the companys board of directors effective immediately mr reisman is a lawyer and certified public accountant with over  years of business experi mirati html pdf add to briefcase file is in briefcase may   mirati therapeutics to present at the  jefferies global healthcare conference san diego may   prnewswire  mirati therapeutics inc nasdaq mrtx a clinical stage targeted oncology biotechnology company will present at the  jefferies global healthcare conference in new york on wednesday june th at  pm et  pm pt charles m baum md phd president and chief executive officer will presen mirati html pdf add to briefcase file is in briefcase may   mirati therapeutics reports first quarter  financial results san diego may   prnewswire  mirati therapeutics inc nasdaq mrtx a clinical stage oncology biotechnology company reported financial results for the first quarter  and provided an update on its product development programs as anticipated  will be an important and defining year for mirati our single agent precision mirati html pdf add to briefcase file is in briefcase mar   mirati therapeutics reports financial results and provides business update for the fourth quarter and full year  san diego march   prnewswire  mirati therapeutics inc nasdaq mrtx the company we our us or mirati today reported financial results for the fourth quarter and year ended december   and provided an update on its product development programs we have made significant progress which positions us to report mirati html pdf add to briefcase file is in briefcase feb   mirati therapeutics to present at leerink partners th annual global healthcare conference san diego feb   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that charles m baum md phd president and ceo of mirati will provide a corporate overview during a fireside chat presentation at the leerink partners th annual global healthcare conference on thursday february   at  pm et am  mirati html pdf add to briefcase file is in briefcase jan   mirati therapeutics announces closing of public offering of common stock and full exercise of underwriters option to purchase additional shares san diego jan   prnewswire  mirati therapeutics inc nasdaq mrtx today announced the closing of its previously announced underwritten public offering of  shares of its common stock at a public offering price of  per share this includes the exercise in full by the underwriter of its option to purchase up to  ad mirati html pdf add to briefcase file is in briefcase jan   mirati therapeutics announces pricing of public offering of common stock san diego jan   prnewswire  mirati therapeutics inc nasdaq mrtx today announced the pricing of an underwritten public offering of  shares of its common stock at a price to the public of  per share in addition and in lieu of common stock mirati is offering to funds affiliated with boxer capital llc prefunded warra mirati html pdf add to briefcase file is in briefcase jan   mirati therapeutics provides update on glesatinib and sitravatinib clinical trials and pipeline programs san diego jan   prnewswire  mirati therapeutics inc mirati or the company nasdaq mrtx today announced data from two ongoing clinical programs including the phase b and phase  trials of glesatinib a spectrum selective kinase inhibitor for the treatment of nonsmall cell lung cancer nsclc patients with genetic alterations of  mirati html pdf add to briefcase file is in briefcase jan   mirati therapeutics announces proposed public offering of common stock san diego jan   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that it intends to offer and sell subject to market and other conditions shares of its common stock mirati expects to grant the underwriters a day option to purchase up to an additional  of the shares of common stock offered in the public offer mirati html pdf add to briefcase file is in briefcase nov   mirati therapeutics reports financial results and provides business update for the third quarter  san diego nov   prnewswire  mirati therapeutics inc nasdaq mrtx the company or mirati today reported financial results for the third quarter ended september   and provided an update on its product development programs we are pleased by the continued progress in all three of our clinical development programs d mirati html pdf add to briefcase file is in briefcase oct   mirati therapeutics appoints chris lemasters to role of executive vice president and chief business officer san diego oct   prnewswire  mirati therapeutics inc nasdaq mrtx today announced the appointment of chris lemasters to the newly created position of executive vice president and chief business officer effective september   chris extensive experience in successfully driving corporate development and strategy at  mirati html pdf add to briefcase file is in briefcase sep   mirati therapeutics announces appointment of dr bruce la carter to board of directors san diego sept   prnewswire  mirati therapeutics inc nasdaq mrtx today announced the appointment of dr bruce la carter to the companys board of directors where he will also serve as a member of the audit committee and compensation committee effective immediately it is a privilege to welcome such a respected and accom mirati html pdf add to briefcase file is in briefcase aug   mirati therapeutics reports financial results and provides business update for the second quarter  san diego aug   prnewswire  mirati therapeutics inc nasdaq mrtx the company or mirati today reported financial results for the second quarter ended june   and provided an update on its product development programs we reported progress across our pipeline during the second quarter including clinical responses mirati html pdf add to briefcase file is in briefcase jun   mirati therapeutics announces change in executive leadership san diego june   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that mark gergen will step down as executive vice president and chief operations officer to pursue other opportunities transitioning over the coming months       we want to thank mark for his important contributions and leadership over the p mirati html pdf add to briefcase file is in briefcase jun   mirati therapeutics provides progress update on current clinical trials san diego june   prnewswire  mirati therapeutics inc nasdaq mrtx today provided an update on three current ongoing clinical programs in patients with nonsmall cell lung cancer nsclc and other solid tumors we are making significant progress in the development of our pipeline as our ongoing clinical programs are showing m mirati html pdf add to briefcase file is in briefcase jun   mirati therapeutics to present at the jefferies  healthcare conference san diego june   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that charles m baum md phd president and ceo of mirati will present a corporate overview at the jefferies  healthcare conference on wednesday june   at  am et  am pt in new york a live audio webcast of the pres mirati html pdf add to briefcase file is in briefcase may   mirati therapeutics to present abstracts on pipeline programs at  american society of clinical oncology asco annual meeting san diego may   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that abstracts on its investigational tyrosine kinase inhibitor candidates glesatinib mgcd and sitravatinib mgcd will be presented at the  american society of clinical oncology asco annual meeting to be held in chicago il from june  mirati html pdf add to briefcase file is in briefcase may   mirati therapeutics reports financial results and business update for the first quarter  san diego may   prnewswire mirati therapeutics inc nasdaq mrtx today reported financial results for the first quarter ended march   and provided an update on its product development programs we are encouraged by the progress made so far this year in advancing our three clinical stage oncology drug candidates which  mirati html pdf add to briefcase file is in briefcase mar   mirati therapeutics to present preclinical data at  american association for cancer research annual meeting san diego march   prnewswire  mirati therapeutics inc nasdaq mrtx today announced it will present preclinical data on two of its three oncology therapies currently in development data on glesatinib mgcd its tyrosine kinase inhibitor targeting met and axl and mocetinostat mgcd its spectrumselective hdac inhibitor wil mirati html pdf add to briefcase file is in briefcase mar   mirati therapeutics announces promotion of jamie a donadio to chief financial officer san diego march   prnewswire  mirati therapeutics inc nasdaq mrtx today announced the promotion of jamie a donadio to senior vice president and chief financial officer effective as of march   mr donadio first joined mirati in  serving as vice president of finance in his new role he will be responsible for a mirati html pdf add to briefcase file is in briefcase mar   mirati therapeutics reports fourth quarter and full year  financial results and provides business update san diego march   prnewswire  mirati therapeutics inc nasdaq mrtx today reported financial results for the fourth quarter and full year ended december   and provided an update on its drug development programs we made significant progress across our entire pipeline in  setting up a potentially transformative year mirati html pdf add to briefcase file is in briefcase mar   mirati therapeutics to present at the barclays global healthcare conference san diego march   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that charles m baum md phd president and ceo of mirati will present a corporate overview at the barclays global healthcare conference on tuesday march   at  pm et  am pt in miami a live audio webcast of the prese mirati html pdf add to briefcase file is in briefcase jan   mirati therapeutics appoints marcy graham vice president investor relations and corporate communications san diego jan   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that marcy graham has been appointed vice president investor relations ir and corporate communications as a seasoned communicator ms graham has more than  years of experience in the biopharmaceutical sector with expertise in growth companies and mirati html pdf add to briefcase file is in briefcase dec   guardant health and mirati therapeutics enter into collaboration on glesatinib mgcd in non small cell lung cancer nsclc trial redwood city calif and san diego dec   prnewswire  guardant health the market leader in liquid biopsies and mirati therapeutics inc mirati nasdaq mrtx a targeted oncology company focusing on genetic and epigenetic drivers of cancer announced today that they have entered into a collaboration for the development of a circu mirati html pdf add to briefcase file is in briefcase dec   foundation medicine and mirati therapeutics collaborate to develop a companion diagnostic for glesatinib mgcd in nonsmall cell lung cancer nsclc cambridge mass and san diego dec   prnewswire  foundation medicine inc nasdaq fmi and mirati therapeutics inc mirati nasdaq mrtx a targeted oncology company focusing on genetic and epigenetic drivers of cancer today announced that they have entered into a collaboration for the development of a companion diagnostic tes mirati html pdf add to briefcase file is in briefcase dec   mirati therapeutics initiates glesatinib mgcd phase  trial in nonsmall cell lung cancer nsclc san diego dec   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the phase  clinical trial of glesatinib mgcd has commenced the company also announced that glesatinib is the proposed generic name for mgcd glesatinib is an inhibitor of the met and axl receptor tyrosine kinase pathways which when al mirati html pdf add to briefcase file is in briefcase dec   mirati therapeutics doses first patient in expansion cohorts of mgcd phase b trial in genetically selected patients san diego dec   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the first patient with nonsmall cell lung cancer nsclc has been dosed in a phase b clinical trial of mgcd the trial will evaluate select patients exhibiting genetic alterations in the tyrosine kinase signaling pathways ret ddr and trk w mirati html pdf add to briefcase file is in briefcase dec   mirati therapeutics to present at the oppenheimer th annual healthcare conference san diego dec  prnewswire  mirati therapeutics inc mirati nasdaq mrtx will be presenting at the oppenheimer th annual healthcare conference on tuesday december   at  am et  am pt in new york charles m baum md phd president and ceo of mirati will provide a corporate overview a live audio  mirati html pdf add to briefcase file is in briefcase nov   mirati therapeutics reports third quarter  financial results and provides business update san diego nov   prnewswire  mirati therapeutics inc mirati nasdaq mrtx today reported financial results for the third quarter ended september   and provided an update on its drug development programs over the last quarter we made substantial progress against our goals including strengthening our balance sheet mirati html pdf add to briefcase file is in briefcase sep   mirati therapeutics presents interim clinical data from ongoing mgcd phase  dose escalation study in patients with advanced solid tumors san diego sept   prnewswire  mirati therapeutics inc mirati nasdaq mrtx an oncology company focusing on genetic and epigenetic drivers of cancer today announced it presented data from the study titled a firstinhuman phase b study of receptor tyrosine kinase rtk inhibitor mgcd in patients with advanced solid tum mirati html pdf add to briefcase file is in briefcase sep   mirati therapeutics announces pricing of public offering of common stock san diego sept   prnewswire  mirati therapeutics inc nasdaq mrtx today announced the pricing of an underwritten public offering of  shares of its common stock at a price to the public of  per share the gross proceeds from this offering are expected to be approximately  million before deducting underwriting d mirati html pdf add to briefcase file is in briefcase sep   mirati therapeutics announces proposed public offering of  million of common stock san diego sept   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that it intends to offer and sell subject to market and other conditions approximately  million of shares of its common stock in an underwritten public offering mirati expects to grant the underwriters a day option to purchase up to an additi mirati html pdf add to briefcase file is in briefcase sep   mirati therapeutics to present clinical data at the european society for medical oncology esmo  european cancer congress san diego sept   prnewswire  mirati therapeutics inc mirati nasdaq mrtx an oncology company focusing on genetic and epigenetic drivers of cancer today announced it will present data on its tyrosine kinase inhibitor mgcd at the esmo  european cancer congress being held in vienna austria from september    mirati html pdf add to briefcase file is in briefcase sep   mgcd demonstrates clinical efficacy with confirmed responses in nsclc patients with met and axl gene amplification denver sept   prnewswire  mirati therapeutics inc mirati nasdaq mrtx an oncology company focusing on genetic and epigenetic drivers of cancer today announced it will present data at the international association of lung cancer iaslc th world conference on lung cancer on the first nonsmall cell lung cancer nsclc patient mirati html pdf add to briefcase file is in briefcase aug   mirati therapeutics to present preclinical and clinical data at the iaslc th world conference on lung cancer san diego aug   prnewswire  mirati therapeutics inc mirati nasdaq mrtx an oncology company focusing on genetic and epigenetic drivers of cancer today announced it will present data on its two tyrosine kinase inhibitors mgcd and mgcd at the international association of lung cancer iaslc th world conference on lung mirati html pdf add to briefcase file is in briefcase aug   mirati therapeutics reports second quarter  financial results and provides business update san diego aug   prnewswire  mirati therapeutics inc mirati nasdaq mrtx today reported financial results for the second quarter ended june   and provided an update on its drug development programs at this years asco meeting we presented initial clinical data on our lead tyrosine kinase inhibitor mgcd whic mirati html pdf add to briefcase file is in briefcase aug   mirati therapeutics and medimmune partner on immunooncology combination in lung cancer san diego and gaithersburg md aug   prnewswire  mirati therapeutics inc mirati nasdaq mrtx an oncology company focusing on genetic and epigenetic drivers of cancer and medimmune the global biologics research and development arm of astrazeneca today announced they have entered into an exclusive clinical trial collaboration mirati html pdf add to briefcase file is in briefcase aug   mirati therapeutics to present at the  wedbush pacgrow healthcare conference san diego aug   prnewswire  mirati therapeutics inc mirati nasdaq mrtx  a targeted oncology company focusing on genetic and epigenetic drivers of cancer will be presenting at the  wedbush pacgrow healthcare conference on tuesday august   at  pm et  am pt in new york charles m baum md phd pr mirati html pdf add to briefcase file is in briefcase may   initial data from ongoing expansion study of mgcd show preliminary evidence of clinical efficacy in heavily pretreated nonsmall cell lung cancer nsclc patients with met gene alterations chicago may   prnewswire  mirati therapeutics inc mirati nasdaq mrtx today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate mgcd as part of the developmental therapeutics category at the  american society of clinical oncolog mirati html pdf add to briefcase file is in briefcase may   mirati therapeutics to present at the jefferies  global healthcare conference san diego may   prnewswire  mirati therapeutics inc mirati nasdaq mrtx will be presenting at the jefferies  global healthcare conference on wednesday june  at  am et  am pt in new york charles m baum md phd president and ceo of mirati will provide a corporate overview a live audio webcast o mirati html pdf add to briefcase file is in briefcase may   mirati therapeutics to provide updates on pipeline programs at  asco annual meeting san diego may   prnewswire  mirati therapeutics inc mirati nasdaq mrtx today announced that the company will provide an update on its investigational targeted tyrosine kinase inhibitor candidates mgcd and mgcd and spectrumselective hdac inhibitor mocetinostat at the  american society of clinical oncology asco a mirati html pdf add to briefcase file is in briefcase may   mirati therapeutics reports first quarter  financial results and provides business update san diego may   prnewswire  mirati therapeutics inc mirati nasdaq mrtx today reported financial results for the first quarter ended march   and provided an update on its drug development programs we continue to make progress across our targeted oncology clinical programs said charles m baum md phd pres mirati html pdf add to briefcase file is in briefcase mar   mirati therapeutics reports fourth quarter and full year  financial results and provides business update san diego march   prnewswire  mirati therapeutics inc mirati nasdaq mrtx today reported financial results for the fourth quarter and twelve months ended december   and provided an update on its drug development programs mirati was built on the premise that the best way to improve outcomes for patients with canc mirati html pdf add to briefcase file is in briefcase feb   mirati therapeutics announces closing of public offering of common stock and full exercise of underwriters option to purchase additional shares san diego feb   prnewswire  mirati therapeutics inc nasdaq mrtx today announced the closing of its previously announced underwritten public offering of  shares of its common stock at a public offering price of  per share this includes the exercise in full by the underwriters of their option to purchase up to  mirati html pdf add to briefcase file is in briefcase jan   mirati therapeutics to present at the leerink global healthcare conference san diego jan   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the company will present a business overview and update at the leerink global healthcare conference on thursday february   at  am eastern time in new york  a live audio webcast of the presentation will be accessible on the in mirati html pdf add to briefcase file is in briefcase jan   mirati therapeutics prices public offering of common stock san diego jan   prnewswire  mirati therapeutics inc nasdaq mrtx today announced the pricing of an underwritten public offering of  shares of its common stock offered at a price to the public of  per share the gross proceeds from this offering to mirati are expected to be  million before deducting underwritin mirati html pdf add to briefcase file is in briefcase jan   mirati therapeutics announces proposed public offering of common stock san diego jan   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that it intends to offer and sell subject to market and other conditions shares of its common stock in an underwritten public offering mirati expects to grant the underwriters a day option to purchase up to an additional  of the shares of comm mirati html pdf add to briefcase file is in briefcase jan   mirati therapeutics doses first patient in phase  study of mocetinostat in bladder cancer patients with genetic alterations of crebbp and ep san diego jan   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the first patient has been dosed in a phase  clinical trial designed to evaluate the efficacy safety and pharmacokinetics of mocetinostat as a treatment for a select group of patients with bladder cancer the trial will enroll patients whose tumo mirati html pdf add to briefcase file is in briefcase jan   mirati therapeutics doses first patient in investigatorsponsored phase  study of mocetinostat in nonhodgkins lymphoma san diego jan   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that memorial sloan kettering cancer center in new york has dosed the first patient in an investigatorsponsored phase  clinical trial of mocetinostat in patients with relapsed and refractory diffuse large bcell lymphoma dlbcl and follicular lympho mirati html pdf add to briefcase file is in briefcase dec   mirati therapeutics doses first patient in expansion cohorts of phase b trial of mgcd in genetically selected patients san diego dec   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the first patient with nonsmall cell lung cancer nsclc has been dosed in a phase b clinical trial of mgcd in selected patients exhibiting genetic alterations of met or axl in this segment of the study one of the expansion cohorts will enr mirati html pdf add to briefcase file is in briefcase nov   mirati therapeutics to present at the th annual piper jaffray healthcare conference san diego nov   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the company will present a business overview and update at the th annual piper jaffray healthcare conference on tuesday december   at  am eastern time in new york  a live audio webcast of the presentation will be accessibl mirati html pdf add to briefcase file is in briefcase nov   mirati therapeutics reports third quarter  financial results and provides business update san diego nov   prnewswire  mirati therapeutics inc mirati nasdaq mrtx today reported financial results for the third quarter ended september   and provided an update on its drug development programs we are excited to report that each of our clinical oncology programs are advancing and are positioned to delive mirati html pdf add to briefcase file is in briefcase nov   michael grey joins mirati therapeutics board of directors san diego nov   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that biotechnology industry veteran michael grey has joined its board of directors mikes extensive experience in the pharmaceutical and biotechnology industries including senior leadership and board positions in several successful companies mirati html pdf add to briefcase file is in briefcase sep   mirati therapeutics to present at biocenturys newsmakers in the biotech industry conference san diego sept   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the company will present a business overview and update at biocenturys st annual newsmakers in the biotech industry conference on friday september   at  am eastern time in new york  a live audio webcast of the presentat mirati html pdf add to briefcase file is in briefcase sep   mirati therapeutics initiates phase  study of mgcd for nonsmall cell lung cancer and other advanced solid tumors san diego sept   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the first patient has been dosed in its phase  clinical study of mgcd in the treatment of patients with advanced solid tumors with an initial focus on nonsmall cell lung cancer nsclc mgcd is a receptor tyrosine kinase rtk inhibitor w mirati html pdf add to briefcase file is in briefcase aug   mirati therapeutics receives orphan designation from us food  drug administration for mocetinostat in diffuse large bcell lymphoma san diego aug   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the us fda has granted orphan drug designation to mocetinostat a spectrum selective hdac inhibitor for diffuse large bcell lymphoma dlbcl in june mocetinostat was granted orphan drug designation as a treatment for myelodysplastic syndrome mirati html pdf add to briefcase file is in briefcase aug   mirati therapeutics reports second quarter  financial results and provides business update san diego aug   prnewswire  mirati therapeutics inc mirati nasdaq mrtx today reported financial results for the second quarter ended june   and provided an update on its drug development programs in the past quarter we expanded the scope of our clinical programs identified compelling patient selection strategi mirati html pdf add to briefcase file is in briefcase jun   mirati therapeutics added to russell  index san diego june   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the company has been added to the russell ® index following the annual reconstitution of its us and global equity indexes on june     inclusion in the russell index charts a step in the rapid growth and maturation of mir mirati html pdf add to briefcase file is in briefcase jun   mirati therapeutics receives orphan drug designation from us food  drug administration for mocetinostat in myelodysplastic syndrome san diego june   prnewswire  mirati therapeutics inc nasdaq mrtx announced that mocetinostat the companys spectrum selective hdac inhibitor has been granted orphan drug designation by the us food  drug administration as a treatment for myelodysplastic syndrome mds mocetinostat is being developed in phase  clinical studies mirati html pdf add to briefcase file is in briefcase jun   mirati therapeutics to present at the th annual jmp securities healthcare conference san diego june   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the company will present at the th annual jmp securities healthcare conference on wednesday june   at  am eastern time in new york   a live audio webcast of the presentation will be accessible on the investors page of the co mirati html pdf add to briefcase file is in briefcase may   mirati therapeutics to present at the jefferies  global healthcare conference san diego may   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the company will present at the jefferies  global healthcare conference on june   at  pm eastern time in new york   a live audio webcast of the presentation will be accessible on the investors page of the companys website a mirati html pdf add to briefcase file is in briefcase may   mirati therapeutics reports first quarter  financial results and provides business update san diego may   prnewswire  mirati therapeutics inc mirati nasdaq mrtx today reported financial results for the first quarter ended march   and provided an update on drug development programs we are making progress in each of our development programs and were on track to produce proof of concept data in multip mirati html pdf add to briefcase file is in briefcase mar   william r ringo joins mirati board of directors san diego march   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that biotechnology industry veteran william ringo has joined its board of directors bill has excellent experience in developing and driving strategies that have enabled success for both large pharmaceutical companies and startup biotechs bi mirati html pdf add to briefcase file is in briefcase mar   mirati therapeutics reports fourth quarter and full year  financial results san diego march   prnewswire  mirati therapeutics inc mirati nasdaq mrtx today reported financial results for the fourth quarter and year ended december   and provided a corporate update  corporate highlights completed transformational corporate reorganization by recruiting highly experienced prec mirati html pdf add to briefcase file is in briefcase feb   mirati therapeutics to present at the  leerink global healthcare conference san diego feb   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the company will present at the  leerink global healthcare conference on thursday february  at  pm eastern time in new york   a live audio webcast of the presentation will be accessible on the investors page of the companys webs mirati html pdf add to briefcase file is in briefcase dec   mirati presents clinical response results of mocetinostat in combination with azacitidine as a treatment for mds san diego dec   prnewswire  mirati therapeutics inc mirati nasdaq mrtx today presented data at the  american society of hematology ash annual meeting demonstrating promising clinical response rates in patients with myelodysplastic syndromes mds patients treated with mocetinostat in combination with azacitidine  separat mirati html pdf add to briefcase file is in briefcase dec   updated presentation time mirati therapeutics to present at the th annual piper jaffray healthcare conference san diego dec   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the company will present at the th annual piper jaffray healthcare conference on wednesday december   at  am eastern time in new york   a live audio webcast of the presentation will be accessible on the investors page of the c mirati html pdf add to briefcase file is in briefcase nov   mirati therapeutics to present at the th annual piper jaffray healthcare conference san diego nov   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that the company will present at the th annual piper jaffray healthcare conference on wednesday december   at  pm eastern time in new york   a live audio webcast of the presentation will be accessible on the investors page of the c mirati html pdf add to briefcase file is in briefcase nov   mirati therapeutics reports third quarter  financial results san diego nov   prnewswire  mirati therapeutics inc mirati nasdaq mrtx today reported financial results for the third quarter and nine months ended september   recent corporate highlights completed financing that generated net proceeds of  million strengthened our worldclass precision medic mirati html pdf add to briefcase file is in briefcase nov   mirati therapeutics to present data on phase  trial of mocetinostat at the th american society of hematology annual meeting san diego nov   prnewswire  mirati therapeutics inc mirati nasdaq mrtx today announced that it will be presenting phase  data on mocetinostat in myelodysplastic syndromes mds at the th american society of hematology annual meeting taking place december  in new orleans data to be presented demonstrates promising clin mirati html pdf add to briefcase file is in briefcase oct   mirati therapeutics prices public offering of common stock san diego oct   prnewswire  mirati therapeutics inc nasdaq mrtx today announced the pricing of an underwritten public offering of  shares of its common stock at a price to the public of  per share  the gross proceeds from this offering to mirati are expected to be approximately  million before deducting under mirati html pdf add to briefcase file is in briefcase oct   mirati therapeutics announces public offering of common stock san diego oct   prnewswire  mirati therapeutics inc nasdaq mrtx today announced that it is offering to sell  shares of its common stock in an underwritten public offering mirati also expects to grant the underwriters a day option to purchase up to an additional  of the shares of common stock offered in the public o mirati html pdf add to briefcase file is in briefcase sep   mirati therapeutics appoints isan chen as chief medical and development officer and adds craig johnson to board of directors san diego californiamarketwired  sep    mirati therapeutics mrtx today announced the appointment of isan chen md as chief medical and development officer as well as the appointment of craig johnson to its bo mirati html pdf add to briefcase file is in briefcase aug   mirati therapeutics reports second quarter  financial results san diego california august   – mirati therapeutics inc “mirati” nasdaq mrtx today reported financial results for the second quarter and first six months ended june   corporate highlights during mirati html pdf add to briefcase file is in briefcase jul   mirati therapeutics to voluntarily delist from tsx san diego california july   – mirati therapeutics inc “mirati therapeutics” today announced that consistent with its previously disclosed plans it has applied to the toronto stock exchange “tsx” to voluntarily delist from trading its shares of common stock  effective at market close on  mirati html pdf add to briefcase file is in briefcase jul   mirati therapeutics to commence trading on the nasdaq san diego california july   – mirati therapeutics inc “mirati therapeutics” or the “company” today announced that the nasdaq capital market “nasdaq” has informed the company that its common stock will commence trading on the nasdaq beginning today july   under the ticker symbol  mirati html pdf add to briefcase file is in briefcase jun   mirati therapeutics and methylgene announce completion of plan of arrangement san diego california and montreal canada june   –methylgene inc “methylgene” tsxmyg and mirati therapeutics inc “mirati therapeutics” today announced the successful completion effective june   of the previously announced plan of arrangement the “arrangement” w mirati html pdf add to briefcase file is in briefcase jun   methylgene shareholders approve the plan of arrangement to reincorporate in the united states as mirati therapeutics inc montreal canada june   –methylgene inc “methylgene” tsxmyg today announced that at its annual and special meeting of shareholders held in montreal quebec the “meeting” that over  of the votes cast by shareholders approved the previously announced plan of arrangement the  methylgene html pdf add to briefcase file is in briefcase jun   methylgene presents clinical data on mocetinostat at the  american society of clinical oncology asco annual meeting montreal canada june   – methylgene inc tsxmyg today announced that clinical data for mocetinostat the spectrum selective histone deacetylase hdac inhibitor was presented at the  asco annual meeting in chicago illinois abstract  – poster – a phase i methylgene html pdf add to briefcase file is in briefcase may   methylgene to present at the jefferies  healthcare conference montreal canada may   – methylgene inc tsxmyg today announced that charles baum md phd president and chief executive officer will present an overview of the company at the jefferies  healthcare conference which will be held in new york city june   the jefferies healthcare conference is one of the methylgene html pdf add to briefcase file is in briefcase may   methylgene to present mocetinostat data at the  american society of clinical oncology asco annual meeting montreal canada may   – methylgene inc tsxmyg today announced that clinical data for mocetinostat the spectrum selective histone deacetylase hdac inhibitor will be presented at the  asco annual meeting to be held in chicago illinois from may st to june   data will be presented from two phase ii clinic methylgene html pdf add to briefcase file is in briefcase may   methylgene reports first quarter  financial results montreal canada may   – methylgene inc “methylgene” or the “company” tsx myg today reported financial results for the first quarter ended march   corporate highlights on may   we announced that subject to court approval and appro methylgene html pdf add to briefcase file is in briefcase may   methylgene announces plan to reincorporate in the united states as mirati therapeutics inc and list on the nasdaq montreal canada may   – methylgene inc “methylgene”tsxmyg today announced that its board of directors the “board” after careful analysis consideration and advice methylgene mirati html pdf add to briefcase file is in briefcase apr   methylgene presents preclinical data on mgcd at the aacr montreal canada april   – methylgene inc tsxmyg today announced that preclinical data for the kinase inhibitor mg was presented at the american association for cancer research aacr annual meeting held in washington dc in a poster entitled “preclinical characteriz methylgene html pdf add to briefcase file is in briefcase mar   methylgene reports results of phase ii trial of mgcd montreal canada march   – methylgene inc tsxmyg today reported topline results from its human efficacy trial trial  with mgcd a novel antifungal agent targeting the fungal enzyme hos  trial  was a randomized multicenter doubleblind placeboco methylgene html pdf add to briefcase file is in briefcase mar   methylgene announces management changes montreal canada march   – methylgene inc “methylgene” or the “company” tsx myg today announced that messrs jeffrey m besterman phd executive vice president research and development and chief scientific officer joe walewicz vice president of business and corporate development a methylgene html pdf add to briefcase file is in briefcase mar   methylgene reports fourth quarter and full year  financial results montreal canada  march   – methylgene inc tsx myg today reported financial results for the fourth quarter and full year ended december   highlights on november   we announced the appointment of charles m baum md phd as president and chief executive  methylgene html pdf add to briefcase file is in briefcase feb   methylgene announces the appointment of mark j gergen as executive vice president and coo montreal canada february   – methylgene inc “methylgene” or the “company” tsx myg today announced that mark j gergen has been appointed to the position of executive vice president and chief operations officer effective immediately in this new role mr gergen will have broad responsibility for business operat methylgene html pdf add to briefcase file is in briefcase dec   methylgene completes enrollment in phase ii trial of mgcd montreal canada december   – methylgene inc tsxmyg today announced that it has completed enrollment in its multicenter randomized doubleblind placebocontrolled trial trial  evaluating mgcd plus fluconazole versus fluconazole alone in patients with moderatetosev methylgene html pdf add to briefcase file is in briefcase nov   methylgene closes cdn million private placement montreal quebec november   – methylgene inc tsxmyg announced today it has completed its previously announced private placement of  units at a subscription price per unit of cdn the “subscription price” each unit consisting of one common share and thirty onehundredths  o methylgene html pdf add to briefcase file is in briefcase nov   methylgene reports third quarter  financial results and provides corporate update montreal canada november   – methylgene inc tsx myg today reported financial results for the third quarter ended september   and provided a corporate update highlights on november   we announced the appointment of dr charles baum md phd as the presiden methylgene html pdf add to briefcase file is in briefcase nov   methylgene announces cdn million private placement montreal quebec november   – methylgene inc tsxmyg announced today its intention to complete a private placement in the united states of cdn million the “offering” the lead investor of the offering is tavistock life sciences “tavistock” an insider of the company and o methylgene html pdf add to briefcase file is in briefcase nov   methylgene announces the appointment of dr charles m baum as president and ceo and changes to the board of directors montreal canada november   – methylgene inc “methylgene” or the “company” tsx myg today announced that charles m baum md phd has been appointed to the position of president and chief executive officer and has joined the company’s board of directors effective immediately me methylgene html pdf add to briefcase file is in briefcase nov   methylgene presents mgcd data at the th eortcnciaacr symposium on molecular targets and cancer therapeutics montreal canada thursday november   – methylgene inc tsx myg today announced that data for the clinicalstage metvegfr inhibitor mgcd was presented at the th eortcnciaacr symposium on molecular targets and cancer therapeutics in dublin ireland in the poster entitled “a novel assay for methylgene html pdf add to briefcase file is in briefcase oct   methylgene to present mgcd data at the th eortcnciaacr symposium on molecular targets and cancer therapeutics montreal canada wednesday october   – methylgene inc tsx myg today announced that preclinical data for its clinicalstage metvegfr inhibitor mgcd will be presented at the th eortcnciaacr symposium on molecular targets and cancer therapeutics taking place in dublin ireland from november  to  methylgene html pdf add to briefcase file is in briefcase oct   methylgene announces presentation of mgcd phase i clinical data at idweek™  montreal canada october   – methylgene inc tsx myg today announced that phase i data for its novel clinicalstage antifungal mgcd were presented at the  idweek™ meeting held in san diego california from october   data describing the safety and pharmacokinetics of mgcd in four phase i clini methylgene html pdf add to briefcase file is in briefcase oct   methylgene provides clinical update on its mgcd novel antifungal therapeutic program montreal canada october   – methylgene inc tsxmyg today provided a clinical update on mgcd the novel orally available antifungal agent clinical data from four phase i safety trials of mgcd will be presented at the  idweek™ meeting to be held in san diego california from october    methylgene html pdf add to briefcase file is in briefcase oct   methylgene presents clinical data on mgcd at the european society for medical oncology esmo  congress montreal canada october   – methylgene inc tsx myg announced that clinical data from its mgcd metvegfrtargeted oncology program were presented today at the european society for medical oncology esmo  congress held in vienna austria  three poster presentations provided updates on the ongoing monotherap methylgene html pdf add to briefcase file is in briefcase sep   methylgene announces change of president and ceo montréal canada september   – methylgene inc “methylgene” or the “company” tsx myg announced today that mr charles grubsztajn has left the company as president and chief executive officer effective immediately and will resign as director of the company  dr martin godbout cha methylgene html pdf add to briefcase file is in briefcase sep   methylgene presents mgcd data at the  annual interscience conference on antimicrobial agents and chemotherapy icaac montreal canada september   – methylgene inc tsxmyg today announced that preclinical data for its novel clinicalstage antifungal mgcd was presented at the nd interscience conference on antimicrobial agents and chemotherapy icaac taking place in san francisco california the poster entitled “ methylgene html pdf add to briefcase file is in briefcase sep   methylgene to present mgcd data at the  annual interscience conference on antimicrobial agents and chemotherapy icaac montreal canada september   – methylgene inc tsxmyg today announced that preclinical data for its novel clinicalstage antifungal mgcd will be presented at the nd interscience conference on antimicrobial agents and chemotherapy icaac taking place in san francisco california from september  to methylgene html pdf add to briefcase file is in briefcase aug   methylgene to present at the  stifel nicolaus healthcare conference montreal canada august   – methylgene inc tsxmyg today announced that mr charles grubsztajn president and chief executive officer will present an overview of the company at the  stifel nicolaus healthcare conference on wednesday september   at  am edt at the four seasons hotel boston massachus methylgene html pdf add to briefcase file is in briefcase aug   methylgene reports second quarter  financial results and provides an update on its clinical programs montreal canada august   – methylgene inc tsx myg today reported financial results for the second quarter ended june   and provided an update on its clinical programs highlights as of august st over one third of the patients have been enrolled in the first phase ii tria methylgene html pdf add to briefcase file is in briefcase jul   methylgene to present at the seventh annual jmp securities healthcare conference montreal canada july   – methylgene inc tsxmyg today announced that mr charles grubsztajn president and chief executive officer will present an overview of the company at the seventh annual jmp securities healthcare conference which will be held at the peninsula new york hotel new york city mr methylgene html pdf add to briefcase file is in briefcase jun   methylgene announces the appointment of dr rodney lappe to its board of directors montreal canada june   – methylgene inc tsx myg today announced the election of rodney lappe phd to the company’s board of directors at the company’s annual meeting of shareholders held earlier today   “over the past year we have significantly enhanced our management team while adding four industry le methylgene html pdf add to briefcase file is in briefcase jun   methylgene to present at the bloom burton  co healthcare investor conference montreal canada june   – methylgene inc tsxmyg today announced that mr charles grubsztajn president and chief executive officer will present an overview of the company at the bloom burton  co healthcare investor conference which will be held at the toronto board of trade on thursday june  methylgene html pdf add to briefcase file is in briefcase jun   methylgene presents mgcd data at the  american society of clinical oncology asco annual meeting montreal canada june   – methylgene inc tsxmyg today announced that clinical data for its metvegfr multi kinase inhibitor mgcd was presented in a poster session at the  asco annual meeting held in chicago illinois the poster entitled “mgcd a multitargeted oral tyrosine kinase recept methylgene html pdf add to briefcase file is in briefcase may   methylgene to present mgcd data at the  american society of clinical oncology asco annual meeting montreal canada may   – methylgene inc tsxmyg today announced that clinical data for its metvegfr kinase inhibitor mgcd will be presented at the  asco annual meeting to be held in chicago illinois from june  to   this poster presentation will highlight the safety profile of mgc methylgene html pdf add to briefcase file is in briefcase may   methylgene to present at biofinance  conference montreal canada may   – methylgene inc tsxmyg today announced that mr joseph walewicz vice president business and corporate development will present an overview of the company at the biofinance  conference which will be held at the st andrew’s club  conference centre in toronto mr walewicz will be pres methylgene html pdf add to briefcase file is in briefcase may   methylgene reports first quarter  financial results and provides an update on clinical programs montreal canada  may   – methylgene inc tsx myg today reported financial results for the first quarter ended march   and provided an update on clinical programs  highlights  rachel w humphrey md was appointed as executive vice president and chief methylgene html pdf add to briefcase file is in briefcase apr   methylgene presents preclinical data for mgcd at the american association for cancer research aacr annual meeting montreal canada april   – methylgene inc tsxmyg today disclosed preclinical data during a presentation for its proprietary multitargeted kinase inhibitor mgcd at the  aacr annual meeting held in chicago illinois results were presented showing the potent inhibition of tumor growth  methylgene html pdf add to briefcase file is in briefcase mar   methylgene to present at the american association for cancer research aacr annual meeting montreal quebec march   – methylgene inc tsxmyg today announced that preclinical data for its multitargeted kinase inhibitor mgcd will be reported in a poster session at the  american association for cancer research aacr annual meeting to be held in chicago illinois from march  to a methylgene html pdf add to briefcase file is in briefcase mar   methylgene announces the appointment of peggy mulligan to its board of directors montreal quebec march   – methylgene inc tsx myg today announced the appointment of peggy mulligan fca to the company’s board of directors “peggy is a financial and audit expert and a well respected business leader we look forward to her guidance as we plan for the future” said charles grubsztajn pre methylgene html pdf add to briefcase file is in briefcase mar   methylgene reports fourth quarter and full year  financial results montreal quebec  march   – methylgene inc tsx myg today reported financial results for the fourth quarter and full year ended december   highlights during the fourth quarter we commenced our first randomized controlled phase  study with mgcd and our two phase  dose escalation  methylgene html pdf add to briefcase file is in briefcase feb   methylgene to present at the th annual bio ceo  investor conference montreal canada  february   – methylgene inc tsx myg announced today that mr charles grubsztajn president and chief executive officer will present a corporate overview of the company on monday february  at  pm est at the th annual bio ceo  investor conference the event is being held at the wa methylgene html pdf add to briefcase file is in briefcase feb   methylgene announces the appointment of dr henry j fuchs to its board of directors montreal quebec february   – methylgene inc tsx myg is pleased to announce the appointment of dr henry j fuchs to the company’s board of directors “dr fuchs is a highly regarded leader in the biotechnology industry and brings a wealth of drug development and management experience at public life science  methylgene html pdf add to briefcase file is in briefcase jan   methylgene announces the appointment of rachel humphrey md as executive vice president and chief medical officer montreal quebec january   – methylgene inc tsx myg today announced the appointment of rachel humphrey md to the post of executive vice president and chief medical officer dr humphrey is board certified in medical oncology and has led the development of multiple oncology agents two of which are currently commerciali methylgene html pdf add to briefcase file is in briefcase page     next last   view all items  add release to briefcase briefcase briefcase printed materials printed materials email alerts email alerts snapshot snapshot rss rss print print email page email page share share search search facebook google linkedin twitter email rss targeted oncology genetic alterations epigenetic alterations pipelineglesatinib mgcd sitravatinib mgcdmocetinostat mgcd patients about the company board of directors scientific advisory board business development careers our team contact us privacy policy terms of use investors news releases events  presentations stock information financials  filings corporate governance investor faqs ir contact email alerts contact mirati  towne centre drive suite  san diego ca   infomiraticom   mirati therapeutics inc  mirati therapeutics  web structure webwizards targeted oncology genetic alterations epigenetic alterations company board of directors scientific advisory board business development careers management team contact pipeline glesatinib mgcd sitravatinib mgcd mocetinostat mgcd patients investors news releases events  presentations stock information financials  filings corporate governance investor faqs ir contact email alerts contact mrtx stock price  mirati therapeutics inc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers ba  t  amd  biib  akam  uhs  rhi  jnpr  latest newsall times eastern p facebook hits  billion users earnings beat live blog p updated stock market ends at record on robust earnings as fed issues policy update p updated trump puts his hands together for ‘the late great abraham lincoln’ p updated the nintendo switch’s sellout launch in many charts p updated year treasury yield falls the most in five weeks after fed statement p updated for transgender americans workplace discrimination isn’t limited to the military p updated your k match may have some strings attached p this is the worst mistake people make at work p why equalweighted stockmarket indexes bounce back faster from bear markets p nutrisystem shares rally on betterthanexpected earnings to be replaced home investing quotes stocks united states mrtx overview compare quotes stock screener earnings calendar sectors nasdaq mrtx us nasdaq join td ameritrade find a broker mirati therapeutics inc watchlist createmrtxalert closed last updated jul    pm edt delayed quote     previous close  advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  k open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap m shares outstanding m public float m beta  rev per employee na pe ratio na eps  yield na dividend na exdividend date na short interest k   of float shorted  average volume k performance  day   month   month  ytd   year  recent news marketwatch other dow jones how led zeppelin would describe this market nov   at  pm et by kevin marder cfo moves toscana energy income francesca’s holdings mirati therapeutics mar   at  pm et on the wall street journal  undervalued stocks insiders are buying mar   at  am et on barrons recent news other news press releases mirati therapeutics mrtx rises stock moves  higher mirati therapeutics inc mrtx shares rose over  in the last trading session jul   at  am et on zackscom mirati perks up  mirati perks up  may   at  pm et on seeking alpha q mirati therapeutics inc q mirati therapeutics inc may   at  pm et on edgar online  edg  q k mirati pharma what differentiates it from the pack apr   at  pm et on seeking alpha k mirati therapeutics inc mar   at  pm et on edgar online  edg  q k insiderinsightscom daily round up  ads mrtx ebtc bas jan   at  am et on seeking alpha insiders roundup adobe fedex jan   at  pm et on gurufocuscom insiderinsightscom daily round up  ads mrtx arnc opk jan   at  am et on seeking alpha insiderinsightscom daily round up  vray bas mrti opk jan   at  pm et on seeking alpha insiderinsightscom daily round up  wpx mrti opk jan   at  am et on seeking alpha mirati prices equity offering shares ease  premarket jan   at  am et on seeking alpha  bargains here were the russell s  worst performers in  jan   at  am et on seeking alpha how mirati therapeutics mrtx stock stands out in a strong industry dec   at  am et on zackscom q mirati therapeutics inc nov   at  pm et on edgar online  edg  q k biggest movers in manufacturing stocks now – gnca ntla bpmc mrtx oct   at  pm et on investorplacecom biggest movers in manufacturing stocks now – lway lee selb agle oct   at  pm et on investorplacecom biggest movers in manufacturing stocks now – ktov juno ccxi cara sep   at  pm et on investorplacecom biggest movers in manufacturing stocks now – clsd sbbp ahc inve sep   at  pm et on investorplacecom biggest movers in manufacturing stocks now – aks mdgl kin mrtx sep   at  pm et on investorplacecom  biotechnology stocks to sell now sep   at  am et on investorplacecom mirati therapeutics to host key opinion leader breakfast on immunooncology combinations on july  in new york mirati therapeutics to host key opinion leader breakfast on immunooncology combinations on july  in new york jul   at  pm et on pr newswire  prf mirati therapeutics to host key opinion leader breakfast on immunooncology combinations on july  in new york mirati therapeutics to host key opinion leader breakfast on immunooncology combinations on july  in new york jul   at  pm et on pr newswire  prf mirati therapeutics announces appointment of neil reisman to the board of directors mirati therapeutics announces appointment of neil reisman to the board of directors jun   at  pm et on pr newswire  prf mirati therapeutics to present at the  jefferies global healthcare conference mirati therapeutics to present at the  jefferies global healthcare conference may   at  pm et on pr newswire  prf mirati therapeutics reports first quarter  financial results mirati therapeutics reports first quarter  financial results may   at  pm et on pr newswire  prf mirati therapeutics reports financial results and provides business update for the fourth quarter and full year  mar   at  pm et on pr newswire  prf mirati therapeutics to present at leerink partners th annual global healthcare conference feb   at  pm et on pr newswire  prf mirati therapeutics announces closing of public offering of common stock and full exercise of underwriters option to purchase additional shares jan   at  pm et on pr newswire  prf mirati therapeutics announces pricing of public offering of common stock jan   at  am et on pr newswire  prf mirati therapeutics provides update on glesatinib and sitravatinib clinical trials and pipeline programs jan   at  pm et on pr newswire  prf mirati therapeutics announces proposed public offering of common stock jan   at  pm et on pr newswire  prf mirati therapeutics reports financial results and provides business update for the third quarter  nov   at  pm et on pr newswire  prf mirati therapeutics appoints chris lemasters to role of executive vice president and chief business officer oct   at  am et on pr newswire  prf mirati therapeutics announces appointment of dr bruce la carter to board of directors sep   at  am et on pr newswire  prf histone deacetylases hdac inhibitors market players trends and forecast    sep   at  pm et on pr newswire  prf mirati therapeutics inc mirati therapeutics inc is a clinicalstage biopharmaceutical company the company focuses on developing a pipeline of oncology products to treat genetic and epigenetic drivers of cancer in selected subsets of cancer patients its product candidates include glesatinib sitravatinib and mocetinostat the company was founded on december   and is headquartered in san diego ca see full profile analyst ratings sell under hold over buy number of ratings  full ratings benzingas top initiations nov   at  am et on benzingacom mirati target lowered from  to  by barclays overweight maintained jun   at  pm et on benzingacom mirati therapeutics shares plunge  jefferies downgrades to hold jun   at  pm et on benzingacom competitors name chg  market cap helix biopharma corp  m sophiris bio inc  m nymox pharmaceutical corp  m travelcenters of america llc  m novelion therapeutics inc  m competitor data provided by partner content trending tickers powered by fb  gild  pypl  jdst  jnug  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience stocks index  markets index bulletin investor alert new york markets after hours market snapshot winners and losers stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  pm edt july   marketstatecountryus new york after marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pfacebook hits  billion users earnings beat live blog pstock market ends at record on robust earnings as fed issues policy update ptrump puts his hands together for ‘the late great abraham lincoln’ pthe nintendo switch’s sellout launch in many charts pyear treasury yield falls the most in five weeks after fed statement pfor transgender americans workplace discrimination isn’t limited to the military pyour k match may have some strings attached pthis is the worst mistake people make at work pwhy equalweighted stockmarket indexes bounce back faster from bear markets pnutrisystem shares rally on betterthanexpected earnings pbuffalo wild wings drop  on high chicken wing costs pbreakingf networks shares fall after weak outlook revenue miss pdonald trump is winning the currency cold war pimco phow to thrive at work when your boss wants you to quit pfacebook hits  billion users earnings beat live blog p‘game of thrones’ science let’s take a closer look at that greyscale p‘game of thrones’ the four biggest takeaways from stormborn’ pbreakingnutrisystem shares jump  following q earnings ptop  most annoying people you may want to unfriend on facebook pif you can buy only one stock or etf make it this one loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stocks index  markets index bulletin investor alert new york markets after hours market snapshot winners and losers stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  pm edt july   marketstatecountryus new york after marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pfacebook hits  billion users earnings beat live blog pstock market ends at record on robust earnings as fed issues policy update ptrump puts his hands together for ‘the late great abraham lincoln’ pthe nintendo switch’s sellout launch in many charts pyear treasury yield falls the most in five weeks after fed statement pfor transgender americans workplace discrimination isn’t limited to the military pyour k match may have some strings attached pthis is the worst mistake people make at work pwhy equalweighted stockmarket indexes bounce back faster from bear markets pnutrisystem shares rally on betterthanexpected earnings pbuffalo wild wings drop  on high chicken wing costs pbreakingf networks shares fall after weak outlook revenue miss pdonald trump is winning the currency cold war pimco phow to thrive at work when your boss wants you to quit pfacebook hits  billion users earnings beat live blog p‘game of thrones’ science let’s take a closer look at that greyscale p‘game of thrones’ the four biggest takeaways from stormborn’ pbreakingnutrisystem shares jump  following q earnings ptop  most annoying people you may want to unfriend on facebook pif you can buy only one stock or etf make it this one loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stockscountryunited states index  markets index bulletin investor alert new york markets after hours market snapshot winners and losers stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies location united states name exchange sector  communique laboratory inc ocqlf ootc software  property insurance holdings inc pih xnas nonlife insurance flowerscom inc cl a flws xnas specialty retail pm industries inc opmz ootc food products st capital bank ca fisb ootc banking st constitution bancorp fccy xnas banking st nrg corp fnrc ootc oil extraction st source corp srce xnas banking  motors inc etfm ootc automobiles st century fox inc cl a foxa xnas broadcasting st century fox inc cl b fox xnas broadcasting vianet group inc adr vnet xnas internetonline nd century group inc xxii xase biotechnology  kid doc inc tvmd ootc healthcare provision u inc twou xnas software xleveraged long etracs linked to wells fargo business development co index  bdcl arcx major international banks xleveraged long etracs wells fargo business development lbdc arcx major international banks d eye solutions inc tdey ootc motion picturesound recording d pioneer systems inc dpsm ootc software d systems corp ddd xnys computersconsumer electronics dicon corp tdcp ootc software dshoppingcom thds ootc mixed retailing dx industries inc dddx ootc computersconsumer electronics i group plc adr tgopy ootc finance companies m co mmm xnys diversified holding companies pea international inc tpnl xotc accounting power energy group inc pspw ootc renewable energy generation tl technologies corp ttmzf ootc advertisingmarketingpublic relations  property management inc ftpm ootc real estate agentsbrokers cable tv international inc catv ootc diversified business services licensing corp fourq ootc diversified business services com ltd adr wbai xnys gambling industries job inc adr jobs xnas employmenttraining services com inc adr wuba xnys consumer services barz international inc barz ootc networking n plus inc fplsf ootc commodity chemicals d global technologies inc sixd ootc computer services  renewable energy corp rnwr ootc multiutilities  energy ltd adr tngry ootc oil extraction  holdings plc eihdf ootc gambling industries point energy partners lp cafd xnas renewable energy generation x inc eght xnas wired telecommunications services a clean slate inc drwn ootc diversified business services aw revenue royalties income fund awrrf ootc restaurants a h belo corp series a ahc xnys publishing a schulman inc shlm xnas commodity chemicals a schulman inc  pfd slmnp ootc commodity chemicals ad makepeace co make ootc farming am castle  co cas xnys wholesalers ao smith corp aos xnys building materialsproducts ap moellermaersk as adr amkby ootc water transportshipping ap moellermaersk as series a amkaf ootc water transportshipping ap moellermaersk as series b amkbf ootc water transportshipping as roma spa asraf ootc recreational services a group inc awon ootc tobacco a networks inc aten xnys computer services a milk co ltd acopf ootc biotechnology aac holdings inc aac xnys healthcare provision aac technologies holdings inc aacaf ootc industrial electronics aac technologies holdings inc adr aacay ootc industrial electronics aaon inc aaon xnas building materialsproducts aap inc aapj ootc food products aar corp air xnys aerospace productsparts aarons inc aan xnys consumer services ab science sa abscf ootc pharmaceuticals ab svensk exportkredit elements linked to mlcx biofuels index total return fue arcx finance companies ab svensk exportkredit elements linked to mlcx grain index total return gru arcx finance companies abt financial corp abto ootc banking abacus mining  exploration corp abcff ootc general mining abakan inc abki ootc industrial products abattis bioceuticals corp attbf ootc biotechnology abaxis inc abax xnas medical equipmentsupplies abb ltd ablzf ootc industrial machinery abb ltd adr abb xnys industrial machinery abbott laboratories abt xnys pharmaceuticals abbvie inc abbv xnys biotechnology abby inc abby ootc oil extraction abcam plc abczf ootc biotechnology abcam plc adr abczy ootc biotechnology abco energy inc abce ootc industrial machinery abcourt mines inc abmbf ootc general mining aben resources ltd abnaf ootc general mining abengoa sa b agoaf ootc construction abeona therapeutics inc abeo xnas biotechnology abeona therapeutics inc wt abeow xnas abercrombie  fitch co anf xnys clothing retail aberdeen asiapacific income fund inc fax xase closedend funds aberdeen asiapacific income investment co ltd abakf ootc closedend funds aberdeen asset management plc abdnf ootc investment advisors aberdeen asset management plc adr abdny ootc investment advisors aberdeen australia equity fund inc iaf xase closedend funds aberdeen chile fund inc ch xase closedend funds aberdeen emerging markets smaller company opportunities fund inc abe xase closedend funds aberdeen global income fund inc fco xase closedend funds aberdeen greater china fund inc gch xnys closedend funds aberdeen indonesia fund inc if xase closedend funds aberdeen international inc aabvf ootc general mining aberdeen israel fund inc isl xase closedend funds aberdeen japan equity fund inc jeq xnys closedend funds aberdeen latin america equity fund inc laq xase closedend funds aberdeen singapore fund inc sgf xnys closedend funds abertis infraestructuras sa adr abrty ootc transportation services ability inc abil xnas precision products ability inc wt abiwf ootc abiomed inc abmd xnas medical equipmentsupplies abitibi royalties inc atbyf ootc general mining able energy inc able ootc gas utilities ablynx nv ablyf ootc biotechnology abm industries inc abm xnys diversified business services abraxas petroleum corp axas xnas oil extraction absecon bancorp ascn ootc banking absolute health  fitness inc ahfi ootc recreational services absolute software corp alswf ootc software abt holdings inc abot ootc precious metals abtech holdings inc abhd ootc industrial machinery abv consulting inc abvn ootc advertisingmarketingpublic relations ac immune sa aciu xnas biotechnology acacia communications inc acia xnas networking acacia diversified holdings inc acca ootc specialty retail acacia mining plc abglf ootc gold acacia research corp  acacia technologies actg xnas diversified business services acadia healthcare co inc achc xnas healthcare provision acadia pharmaceuticals inc acad xnas biotechnology acadia realty trust akr xnys acadian timber corp acazf ootc forestry  wood products acasti pharma inc acst xnas pharmaceuticals accelera innovations inc acnv ootc healthcare provision accelerate diagnostics inc axdx xnas biotechnology accelerize inc aclz xotc life insurance acceleron pharma inc xlrn xnas biotechnology accenture plc cl a acn xnys diversified business services access national corp ancx xnas banking access power inc accr ootc wired telecommunications services access worldwide communications inc awwc ootc advertisingmarketingpublic relations acciona sa acxif ootc construction acco brands corp acco xnys nondurable household products accor sa acrff ootc hotels accor sa adr accyy ootc hotels accordia golf co ltd acgff ootc recreational services accredited mortgage loan reit trust  perp cum pfd series a ahhap ootc mortgages accretive health inc achi ootc healthcare provision accuray inc aray xnas medical equipmentsupplies accuride corp acw xnys auto  commercial vehicle parts acelrx pharmaceuticals inc acrx xnas pharmaceuticals acer inc gdr reg s aceyy ootc computersconsumer electronics acerus pharmaceuticals corp trlpf ootc biotechnology aceto corp acet xnas specialty chemicals achaogen inc akao xnas biotechnology achillion pharmaceuticals inc achn xnas biotechnology aci worldwide inc aciw xnas software «» log in  pm edt july   marketstatecountryus new york after marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pfacebook hits  billion users earnings beat live blog pstock market ends at record on robust earnings as fed issues policy update ptrump puts his hands together for ‘the late great abraham lincoln’ pthe nintendo switch’s sellout launch in many charts pyear treasury yield falls the most in five weeks after fed statement pfor transgender americans workplace discrimination isn’t limited to the military pyour k match may have some strings attached pthis is the worst mistake people make at work pwhy equalweighted stockmarket indexes bounce back faster from bear markets pnutrisystem shares rally on betterthanexpected earnings pbuffalo wild wings drop  on high chicken wing costs pbreakingf networks shares fall after weak outlook revenue miss pdonald trump is winning the currency cold war pimco phow to thrive at work when your boss wants you to quit pfacebook hits  billion users earnings beat live blog p‘game of thrones’ science let’s take a closer look at that greyscale p‘game of thrones’ the four biggest takeaways from stormborn’ pbreakingnutrisystem shares jump  following q earnings ptop  most annoying people you may want to unfriend on facebook pif you can buy only one stock or etf make it this one loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  mrtx stock price  mirati therapeutics inc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers ba  t  amd  biib  akam  uhs  rhi  jnpr  latest newsall times eastern p facebook hits  billion users earnings beat live blog p updated stock market ends at record on robust earnings as fed issues policy update p updated trump puts his hands together for ‘the late great abraham lincoln’ p updated the nintendo switch’s sellout launch in many charts p updated year treasury yield falls the most in five weeks after fed statement p updated for transgender americans workplace discrimination isn’t limited to the military p updated your k match may have some strings attached p this is the worst mistake people make at work p why equalweighted stockmarket indexes bounce back faster from bear markets p nutrisystem shares rally on betterthanexpected earnings to be replaced home investing quotes stocks united states mrtx overview compare quotes stock screener earnings calendar sectors nasdaq mrtx us nasdaq join td ameritrade find a broker mirati therapeutics inc watchlist createmrtxalert closed last updated jul    pm edt delayed quote     previous close  advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  k open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap m shares outstanding m public float m beta  rev per employee na pe ratio na eps  yield na dividend na exdividend date na short interest k   of float shorted  average volume k performance  day   month   month  ytd   year  recent news marketwatch other dow jones how led zeppelin would describe this market nov   at  pm et by kevin marder cfo moves toscana energy income francesca’s holdings mirati therapeutics mar   at  pm et on the wall street journal  undervalued stocks insiders are buying mar   at  am et on barrons recent news other news press releases mirati therapeutics mrtx rises stock moves  higher mirati therapeutics inc mrtx shares rose over  in the last trading session jul   at  am et on zackscom mirati perks up  mirati perks up  may   at  pm et on seeking alpha q mirati therapeutics inc q mirati therapeutics inc may   at  pm et on edgar online  edg  q k mirati pharma what differentiates it from the pack apr   at  pm et on seeking alpha k mirati therapeutics inc mar   at  pm et on edgar online  edg  q k insiderinsightscom daily round up  ads mrtx ebtc bas jan   at  am et on seeking alpha insiders roundup adobe fedex jan   at  pm et on gurufocuscom insiderinsightscom daily round up  ads mrtx arnc opk jan   at  am et on seeking alpha insiderinsightscom daily round up  vray bas mrti opk jan   at  pm et on seeking alpha insiderinsightscom daily round up  wpx mrti opk jan   at  am et on seeking alpha mirati prices equity offering shares ease  premarket jan   at  am et on seeking alpha  bargains here were the russell s  worst performers in  jan   at  am et on seeking alpha how mirati therapeutics mrtx stock stands out in a strong industry dec   at  am et on zackscom q mirati therapeutics inc nov   at  pm et on edgar online  edg  q k biggest movers in manufacturing stocks now – gnca ntla bpmc mrtx oct   at  pm et on investorplacecom biggest movers in manufacturing stocks now – lway lee selb agle oct   at  pm et on investorplacecom biggest movers in manufacturing stocks now – ktov juno ccxi cara sep   at  pm et on investorplacecom biggest movers in manufacturing stocks now – clsd sbbp ahc inve sep   at  pm et on investorplacecom biggest movers in manufacturing stocks now – aks mdgl kin mrtx sep   at  pm et on investorplacecom  biotechnology stocks to sell now sep   at  am et on investorplacecom mirati therapeutics to host key opinion leader breakfast on immunooncology combinations on july  in new york mirati therapeutics to host key opinion leader breakfast on immunooncology combinations on july  in new york jul   at  pm et on pr newswire  prf mirati therapeutics to host key opinion leader breakfast on immunooncology combinations on july  in new york mirati therapeutics to host key opinion leader breakfast on immunooncology combinations on july  in new york jul   at  pm et on pr newswire  prf mirati therapeutics announces appointment of neil reisman to the board of directors mirati therapeutics announces appointment of neil reisman to the board of directors jun   at  pm et on pr newswire  prf mirati therapeutics to present at the  jefferies global healthcare conference mirati therapeutics to present at the  jefferies global healthcare conference may   at  pm et on pr newswire  prf mirati therapeutics reports first quarter  financial results mirati therapeutics reports first quarter  financial results may   at  pm et on pr newswire  prf mirati therapeutics reports financial results and provides business update for the fourth quarter and full year  mar   at  pm et on pr newswire  prf mirati therapeutics to present at leerink partners th annual global healthcare conference feb   at  pm et on pr newswire  prf mirati therapeutics announces closing of public offering of common stock and full exercise of underwriters option to purchase additional shares jan   at  pm et on pr newswire  prf mirati therapeutics announces pricing of public offering of common stock jan   at  am et on pr newswire  prf mirati therapeutics provides update on glesatinib and sitravatinib clinical trials and pipeline programs jan   at  pm et on pr newswire  prf mirati therapeutics announces proposed public offering of common stock jan   at  pm et on pr newswire  prf mirati therapeutics reports financial results and provides business update for the third quarter  nov   at  pm et on pr newswire  prf mirati therapeutics appoints chris lemasters to role of executive vice president and chief business officer oct   at  am et on pr newswire  prf mirati therapeutics announces appointment of dr bruce la carter to board of directors sep   at  am et on pr newswire  prf histone deacetylases hdac inhibitors market players trends and forecast    sep   at  pm et on pr newswire  prf mirati therapeutics inc mirati therapeutics inc is a clinicalstage biopharmaceutical company the company focuses on developing a pipeline of oncology products to treat genetic and epigenetic drivers of cancer in selected subsets of cancer patients its product candidates include glesatinib sitravatinib and mocetinostat the company was founded on december   and is headquartered in san diego ca see full profile analyst ratings sell under hold over buy number of ratings  full ratings benzingas top initiations nov   at  am et on benzingacom mirati target lowered from  to  by barclays overweight maintained jun   at  pm et on benzingacom mirati therapeutics shares plunge  jefferies downgrades to hold jun   at  pm et on benzingacom competitors name chg  market cap helix biopharma corp  m sophiris bio inc  m nymox pharmaceutical corp  m travelcenters of america llc  m novelion therapeutics inc  m competitor data provided by partner content trending tickers powered by fb  gild  pypl  jdst  jnug  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience targeted oncology cancer patient treatment research  mirati therapeutics inc no menu assigned expertly targetingdrivers of cancer inselect patientpopulations the latest news at mirati therapeutics jul   mirati therapeutics to host key opinion leader breakfast on immunooncology combinations on july  in new york jun   mirati therapeutics announces appointment of neil reisman to the board of directors may   mirati therapeutics to present at the  jefferies global healthcare conference a targeted oncology company developing breakthrough medicines for precisely defined patient populations mirati therapeutics is transforming the treatment of patients with cancer by targeting the genetic changes in tumor cells that result in uncontrolled tumor growth and spread our precision oncology strategy seeks to treat the patients most likely to benefit and is driven by  drugs that target very specific genetic mutations that cause cancer and  genomic tests that identify patients who carry those driver mutations the promise of this approach includes better patient outcomes more efficient cancer treatment and faster drug development learn more about mirati targeted oncology genetic alterations epigenetic alterations pipelineglesatinib mgcd sitravatinib mgcdmocetinostat mgcd patients the amethyst study about the company our team board of directors scientific advisory board business development careers contact us privacy policy terms of use investors news releases events  presentations stock information financials  filings corporate governance investor faqs ir contact email alerts contact mirati  towne centre drive suite  san diego ca   infomiraticom investor relations temre johnson ir  corporate communications    mirati therapeutics inc  mirati therapeutics  web structure webwizards targeted oncology genetic alterations epigenetic alterations company management team board of directors scientific advisory board business development careers contact pipeline glesatinib mgcd sitravatinib mgcd mocetinostat mgcd patients amethyst study investors news releases events  presentations stock information financials  filings corporate governance investor faqs ir contact email alerts contact mirati therapeutics inc mrtxph company profile  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states profile mirati therapeutics inc mrtxph related topics stocksstock screenerhealthcarebiotechnology  medical research overview news key developments people charts financials analysts research pulse mrtxph on philadelphia stock exchange usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  full description mirati therapeutics inc incorporated on april   is a clinicalstage biopharmaceutical company the company is focused on developing a pipeline of targeted oncology products the companys clinical pipeline consists of three product candidates mgcd mgcd and mocetinostat mocetinostat has completed approximately  clinical trials in over  patients with a range of hematologic malignancies and solid tumorsmgcdmgcd is an orallybioavailable small molecule kinase inhibitor of met and axl receptor tyrosine kinases rtks mgcd is in development for the treatment of solid tumors such as nonsmall cell lung cancer nsclc and other solid tumors including gastroesophageal cancers and squamous cell carcinoma of the head and neck hnscc mgcd is in phase ib clinical developmentmgcdmgcd is an orallybioavailable small molecule spectrumselective kinase inhibitor in development for the treatment of solid tumors with a focus on genetic alterations involving the ret ddr and trk rtk families as well as chrq amplicons and cbl inactivating mutations mgcd is in the dose escalation phase of phase i clinical development it plans to focus on solid tumors exhibiting genetic alterations which result in dysregulation of these key drivers of tumor growth initially in nsclcmocetinostatmocetinostat is an orallybioavailable spectrumselective histone deacetylase hdac inhibitor which is in phase ii development mocetinostat is being developed for the second line treatment of patients with bladder cancer and nonhodgkins lymphoma nhl specifically focusing on diffuse large bcell lymphoma dlbcl and follicular lymphoma flthe company competes with abbvie inc astrazeneca plc exelixis inc glaxosmithkline plc ignyta inc incyte corporation merck kgaa nantpharma llc novartis ag pfizer inc sanofi s a astellas pharma inc bergenbio as tolero inc acetylon pharmaceuticals inc chroma therapeutics ltd huya bioscience international shenzen chipscreen biosciences ltd syndax pharmaceuticals inc celgene corporation curis inc mei pharma inc merck  co inc pharmacyclics inc gilead sciences inc bayerschering pharmaceutical boehringer ingelheim ag bristolmyers squibb eisai co ltd eli lilly and company f hoffmannlaroche ltd johnson  johnson taiho takeda pharmaceutical co and compugen limited » full overview of mrtxph company address mirati therapeutics inc  towne centre dr ste san diego   ca    p f  company web links home page officers  directors name compensation rodney lappe  charles baum  jamie donadio  isan chen  christopher lemasters  » more officers  directors mirati therapeutics inc news » more mrtxph news related topics stocksstock screenerhealthcarebiotechnology  medical research mrtx profile  mirati therapeutics inc stock  yahoo financehomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoreyahoosearchsearchus markets closedsp  dow  listentop economists debate state of labor marketyahoo finances nicole sinclair moderates a panel of leading economists at the state of the labor market summitmirati therapeutics inc mrtxnasdaqcm  nasdaqcm real time price currency in usdadd to watchlist at close pm edtpeople also watchrxdxmgnximdzkptiitcisummaryconversationsstatisticsprofilefinancialsoptionsholdershistorical dataanalystsmirati therapeutics inc towne centre drivesuite san diego ca united stateshttpwwwmiraticomsector healthcareindustry biotechnologyfull time employees key executivesnametitlepayexercisedagedr rodney w lappe phdexec chairmannanadr charles m baum md phdchief exec officer pres and directorknadr james christensen phdchief scientific officer and sr vpknadr isan chen mdchief medical  devel officer and exec vpknamr jamie a donadio phdchief financial officer and sr vpnanaamounts are as of december   and compensation values are for the last fiscal year ending on that date pay is salary bonuses etc exercised is the value of options exercised during the fiscal year currency in usddescriptionmirati therapeutics inc a clinicalstage biopharmaceutical company develops a pipeline of oncology products the companys clinical stage product candidates include glesatinib an orallybioavailable potent small molecule kinase inhibitor that is in phase ii clinical trials for the treatment of nonsmall cell lung cancer nsclc patients with genetic alterations of met and in phase ib clinical trials in patients with genetic alterations of met and axl in nsclc and other solid tumors its clinical stage product candidates also comprise sitravatinib an orallybioavailable potent small molecule spectrumselective kinase inhibitor which is in phase ii clinical trials for the treatment of solid tumors such as nsclc and metastatic renal cell carcinoma as well as in phase ib clinical trials to treat nsclc patients with ret chrq cbl and axl genetic alterations and mocetinostat an orally administered spectrumselective class  histone deacetylase inhibitor which is in phase ibii clinical trials in combination with durvalumab for the treatment of patients with nsclc the company has a collaboration agreement with foundation medicine inc and guardant health inc to explore development of their platforms as companion diagnostics for glesatinib mirati therapeutics inc is headquartered in san diego californiacorporate governancemirati therapeutics inc’s iss governance qualityscore as of july   is  the pillar scores are audit  board  shareholder rights  compensation corporate governance scores courtesy of institutional shareholder services iss scores indicate decile rank relative to index or region a decile score of  indicates lower governance risk while a  indicates higher governance riskyahoo small businessdata disclaimerhelpsuggestionsprivacyabout our adsterms updated mirati therapeutics inc private company information  bloomberg july    pm et biotechnology company overview of mirati therapeutics inc snapshot people company overview mirati therapeutics inc a clinicalstage biopharmaceutical company develops a pipeline of oncology products the company’s clinical stage product candidates include glesatinib an orallybioavailable potent small molecule kinase inhibitor that is in phase ii clinical trials for the treatment of nonsmall cell lung cancer nsclc patients with genetic alterations of met and in phase ib clinical trials in patients with genetic alterations of met and axl in nsclc and other solid tumors its clinical stage product candidates also comprise sitravatinib an orallybioavailable potent small molecule spectrumselective kinase inhibitor which is in phase ii clinical trials for the treatment mirati therapeutics inc a clinicalstage biopharmaceutical company develops a pipeline of oncology products the company’s clinical stage product candidates include glesatinib an orallybioavailable potent small molecule kinase inhibitor that is in phase ii clinical trials for the treatment of nonsmall cell lung cancer nsclc patients with genetic alterations of met and in phase ib clinical trials in patients with genetic alterations of met and axl in nsclc and other solid tumors its clinical stage product candidates also comprise sitravatinib an orallybioavailable potent small molecule spectrumselective kinase inhibitor which is in phase ii clinical trials for the treatment of solid tumors such as nsclc and metastatic renal cell carcinoma as well as in phase ib clinical trials to treat nsclc patients with ret chrq cbl and axl genetic alterations and mocetinostat an orally administered spectrumselective class  histone deacetylase inhibitor which is in phase ibii clinical trials in combination with durvalumab for the treatment of patients with nsclc the company has a collaboration agreement with foundation medicine inc and guardant health inc to explore development of their platforms as companion diagnostics for glesatinib mirati therapeutics inc is headquartered in san diego california detailed description  towne centre drivesuite san diego ca united states employees phone  wwwmiraticom key executives for mirati therapeutics inc dr charles m baum md phd chief executive officer president and director age  total annual compensation k dr isan chen md chief medical  development officer and executive vice president age  total annual compensation k dr james christensen phd chief scientific officer and senior vice president age  total annual compensation k compensation as of fiscal year  mirati therapeutics inc key developments mirati therapeutics inc appoints neil reisman to its board of directors jun   mirati therapeutics inc announced the appointment of neil reisman to the companys board of directors effective immediately mr reisman is a lawyer and certified public accountant with over  years of business experience with emphasis on finance operations legal tax and transactional experience he will provide similar guidance while serving on miratis board of directors mirati therapeutics inc presents at jefferies  global healthcare conference jun  pm may   mirati therapeutics inc presents at jefferies  global healthcare conference jun  pm venue grand hyatt  e nd st new york new york united states speakers charles m baum chief executive officer president and director mirati therapeutics inc presents at bio international conference  jun  pm may   mirati therapeutics inc presents at bio international conference  jun  pm venue san diego convention center san diego ca  united states speakers jessica m corson senior director of business development similar private companies by industry company name region n labs inc united states andme inc united states c tech corporation inc united states v biosciences inc united states bar biologics inc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact mirati therapeutics inc please visit wwwmiraticom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close mirati therapeutics inc nasdaqmrtx mirati therapeutics inc mrtx product news news  stocknewscom     follow us stocktwits twitter mirati therapeutics inc mrtx product news news mrtx – company provides progress update on current clinical trials phase  trial for mocetinostat in combination with durvalumab initiated and enrolling patients jun    am  by stocknewscom staff product news key facts surrounding this news item mrtx had a powr rating of d sell coming into today mrtx was  above its day moving average coming into today mrtx was  above its day moving average coming into today mrtx was  below its day moving average coming into today mrtx was  below its day moving average coming into today mrtx was  below its day moving average coming into today mrtx had returned  yeartodate leading up to today’s news versus a  return from the benchmark sp  during the same period more info about mirati therapeutics inc mrtx mirati therapeutics develops molecularly targeted cancer treatments that are intended to inhibit tumor growth the company was founded in  and is based in san diego california view our full mrtx ticker page with ratings news and more mrtx at a glance mrtx current powr rating™ overall powr rating™ mrtx current price   more mrtx ratings data and news mrtx price reaction the day of this event jun  mrtx closing price mrtx volume from avgleading up to this eventmrtx mo returnafter this eventmrtx day returnmrtx day returnmrtx day return mrtx price chart more mirati therapeutics inc mrtx news view all eventdate symbol news detail start price end price change powr rating loading please wait view all mrtx news page generated in  seconds microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft mirati therapeutics inc mylgf  stock predictions  price targets facebook autocomplete demo post a rating  month price target   home trending sign up log in mirati therapeutics inc mylgf      utc median target price  positive ratings  view all analyst ratings for mylgf » facebook autocomplete demo post a rating  month price target   home trending sign up log in analyst ranking   name measured ratings sucess rate avg return  mizuho      credit suisse      jefferies      cantor fitzgerald      bank of america merrill lynch      jmp securities      goldman sachs      raymond james      fbr capital markets      william blair     flashratings  contact us facebook autocomplete demo post a rating  month price target   trending sign up log in contact flashratings your emotional state excited confused worried upset panicked angry flashratings  principles facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings principles  flashratings mission is to provide you  the investor  with as much honest and professional research on your investments as possible  we believe its much better to get a multitude of credible opinions on an investment than to arbitrarily follow any single advisor  be it your banker a friend or a tv pundit  flashratings does not provide advice our job is to accurately and objectively report on analysts credible research and opinions the only advice flashratings will ever give you is to absorb as much fundamental research and different opinions as possible and make your own decisions  flashratings favors covering analysts with proven track records but will cover all analysts as long as their research is honest and professional sign up » flashratings  about us facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings  all research for my stocks the most comprehensive equity research coverage available online never miss a single piece of research upgrade downgrade or target price change by any analyst firm on any stock equity research by professional analysts  especially their rationales more than their forecasts  contains far more interesting and important information about the actual fundamentals of the traded companies than can be gathered from conventional news reports our mission is to unlock access to valuable research on stocks for all retail investors professionals institutions take advantage of our costeffective subscriptions to have flashratingss comprehensive realtime feed delivered into your intranet and trading floor platforms institutional subscriptions websites become a content licensing partner and display flashratingss popular news feed on your website content licensing advertisers advertise with us and have flashratings readers with attractive demographics take advantage of your products advertising targeted oncology cancer patient treatment research  mirati therapeutics inc no menu assigned expertly targetingdrivers of cancer inselect patientpopulations the latest news at mirati therapeutics jul   mirati therapeutics to host key opinion leader breakfast on immunooncology combinations on july  in new york jun   mirati therapeutics announces appointment of neil reisman to the board of directors may   mirati therapeutics to present at the  jefferies global healthcare conference a targeted oncology company developing breakthrough medicines for precisely defined patient populations mirati therapeutics is transforming the treatment of patients with cancer by targeting the genetic changes in tumor cells that result in uncontrolled tumor growth and spread our precision oncology strategy seeks to treat the patients most likely to benefit and is driven by  drugs that target very specific genetic mutations that cause cancer and  genomic tests that identify patients who carry those driver mutations the promise of this approach includes better patient outcomes more efficient cancer treatment and faster drug development learn more about mirati targeted oncology genetic alterations epigenetic alterations pipelineglesatinib mgcd sitravatinib mgcdmocetinostat mgcd patients the amethyst study about the company our team board of directors scientific advisory board business development careers contact us privacy policy terms of use investors news releases events  presentations stock information financials  filings corporate governance investor faqs ir contact email alerts contact mirati  towne centre drive suite  san diego ca   infomiraticom investor relations temre johnson ir  corporate communications    mirati therapeutics inc  mirati therapeutics  web structure webwizards targeted oncology genetic alterations epigenetic alterations company management team board of directors scientific advisory board business development careers contact pipeline glesatinib mgcd sitravatinib mgcd mocetinostat mgcd patients amethyst study investors news releases events  presentations stock information financials  filings corporate governance investor faqs ir contact email alerts contact bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one